Home

Superior Care

At Genisis Biotechnologies our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey.

Our clinically proven research also allows us to help educate, inform and simplify access to patients all forms of medical marijuana that works for different types of conditions. Our goal is to ensure that patients and sufferers receive and benefit from the most effective treatment for all chronic conditions and pain.

Through cutting-edge research, we are not only constantly developing a variety of clinically proven medicinal marijuana products, but also establishing different methods in which the entire medical community, and patients alike, can administer these treatments to achieve the most beneficial results.

We are here to guide the entire medical profession and all of its patients by the hand at every step of the way. As industry experts, we are advancing medicinal marijuana research, development and product production with absolute dedication to ensure the highest possible quality and clinically proven products.

Regulatory Standards

Our compliance with regulatory standards, and our mission to product improvement and innovation, makes us one of the sector’s most stable and fastest growing companies that provides clinical research and development used for the production of accredited medical marijuana products.

From our inception in 2011 we were committed in providing clinically proven research that would ensure superior care and support to all patients seeking marijuana as a medical alternative to their symptom relief and ultimate healing. Our company’s focus is to establish and provide the most beneficial treatments for chronic conditions and the relief of pain that patients worldwide demand.

On our journey towards reaching the best care and products from this healing plant, we are committed to move forward by improving our research and production by using the latest technology available today.

Backed by our clinical trials, and the proven healthcare, healing experiences of patients that have trusted our medical marijuana products, our belief is that with continued research and development, we will come to a point in the future where medicinal marijuana becomes the preferred course of treatment by the entire medical profession, compared to the synthetic pharmaceutical treatments used today.

Our Duty

We believe that it is our duty to further pursue our clinical research and development programs to create treatments and cures for chronic conditions that currently have considerable unmet needs, and as such are not curable today.

Genisis Biotechnologies’ groundbreaking research has already opened many doors to clinically proven treatments in the medical profession today. Our research has contributed to new findings that leads to producing new and effective medicinal products that treat chronic conditions that the world has been struggling with for many years now. Because of the improvements in quality and delivery methods, Genisis Biotechnologies now has established tremendous opportunities to create substantial value for shareholders and investors alike.

We believe that our success comes from our solid team of in-house leaders, research scientists, analytical chemists and clinicians. Furthermore, our knowledge is enhanced by strategic partnerships with medical schools and universities, intellectual property experts and company partners that share one common goal: to make the future of medicine a better place for the next generations to come. Our team’s dedication and hard work are at the root of our success. Without them, Genisis Biotechnologies’ success would not possible.

Our company believes that marijuana, science and technology, and a team’s dedication can search and produce answers to questions that have remained as yet unsolved by the medical industry today. With the right people and technology firmly in place we are very proud of our position as a market leader in the clinical and medical marijuana bio-technology sector, with a focus on finding cures for many different and new chronic conditions that plagues mankind today.




Our Management Team

Dedicated to the clinical research and development of medicinal marijuana.

All of Genisis Biotechnologies’ management team are dedicated to the research and development of medicinal marijuana and all have a single-minded approach to ensuring the continued advancement of its clinically proven benefits are maintained.

Clive Mendelson

Chief Executive Officer

Clive Mendelson serves as our Chief Executive Officer and has more than 30 years of executive, operational and commercial leadership experience in the bio-pharmaceutical industry, particularly in leading CNS transdermal patch and gel products which has helped CAMM Pharmaceuticals develop their own products adopting similar dispensing methods.

Prior to Genisis Biotech, Clive served as CEO of two publicly traded companies. Most recently, he was the CEO of a bio-tech company which was acquired by one of the world’s largest pharmaceutical companies during a 5-year tenure.

He assisted with the company acquiring FDA approval of its lead product, which was the first transdermal patch for migraine, to pre-launch before successfully over-seeing the sale of the company. He has also served as the CEO of a NASDAQ listed pharmaceutical company, where under his leadership, sales grew from $42 million to more than $90 million in just 4 years and market capitalization increased from $200 million to more than $500 million.

Jeremy received a B.S. in Molecular Biology from the University of Toronto - Mississauga, a Ph.D. in Biochemistry from York University, and conducted his postdoctoral training in biophysics and biology at The Canadian Cancer Society Saskatchewan.

Drew Lancaster, Ph.D.

Head of Product Development

Dr. Lancaster is our Head of Product Development and is responsible for the day-to-day management of our research and development activities as well as supporting the commercialization of the company’s products.

Dr. Lancaster has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology.

Dr. Lancaster also has more than 30 years of executive, development and operational experience in the bio-pharmaceutical industry, particularly in CNS product development including epilepsy, pain, depression and schizophrenia. He has been responsible for more than 10 regulatory submissions and approvals of new pharmaceutical products, including transdermal patch and gel products.

Prior to joining Genisis Biotech, Dr. Lancaster held scientific leadership roles with some of Canada’s leading medical institutions and also held research positions with privately owned and publicly listed pharmaceutical companies in the U.S.

Dr. Lancaster has a broad range of development experience, starting from early drug discovery and clinical trials through to regulatory approval and commercial launch. He completed his Ph.D. at the University of Alberta Faculty of Science.

Sarah Blackwall, Ph.D.

Director of Formulation Sciences

Dr. Sarah Blackwall, Ph.D., has more than 15 years of experience developing formulations of pharmaceuticals, biologicals, and vaccines for alternative routes of delivery, including sublingual, nasal, transdermal, and inhalation

Previously, Dr. Blackwall successfully led the effort to develop, achieve regulatory approval, and complete manufacturing of the first tincture and transdermal patch used in the treatment of severe pain relief.

Dr. Blackwall also led the formulation and spray-drying process development of the first inhaled dry powder measles vaccine to successfully complete a Phase 1 clinical trial. She has a broad experience in early-stage R&D, formulation and process development, and technology transfer for GMP manufacturing.

Prior to joining Genisis Biotech she served in a variety of executive roles with Pfizer for more than 20 years and has over-seen technical and project leadership roles at the McGill University, Quebec.

Dr. Blackwall graduated with a Ph.D. in Biochemistry and Genetics from York University, Toronto and conducted post-doctoral research at the Wilfrid Laurier University, Waterloo, Canada.

Martin Milligan, PharmD

Director of Medical Services

Martin Milligan, PharmD, has served as our Director of Medical Services since July 2011. Martin is a senior pharmaceutical executive with more than 30 years of experience in clinical development, medical affairs and commercialization in CNS therapy areas.

During his career, he has led numerous successful clinical development programs, regulatory approvals and product launches. Prior to joining Genisis Biotech, he served as head of Medical Affairs for a large NYSE listed medical research company.

There he was instrumental in the clinical development of their international medical affairs’ teams in neurology and psychiatry. Additionally, he led several successful commercial product launches for some of the more accepted medicines currently being used by psychiatrists worldwide. He earned his Doctor of Pharmacy degree at the University of British Columbia and his MBA at the Trinity Western University.

He has several published articles relating to the use of medical marijuana and the differing experiences between men and women who use medicinal marijuana for Parkinson’s disease tremor and has recently completed a clinical report on the findings.

Martin also serves on the Board of Visitors at The School of Pharmacy at the University of Waterloo and as a board member of several non-profit medical organizations.

Don Jennings

Director of Corporate Development

Don Jennings serves as Genisis Biotech’s Director of Corporate Development. Mr. Jennings is a seasoned executive who has held management, financial and strategic planning roles in his 28-year tenure in the pharmaceutical industry.

Prior to Genisis Biotech, he was Senior Vice President, Chief Financial Officer, at one of the world’s most well-respected pharmaceutical giants and focused on their self-administered parenteral product range. He has also held the role of Chief Financial Officer with Auxilium Pharmaceuticals, as well as additional general management, business development and strategic planning responsibilities with them.

Mr. Jennings has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Vice President with a Canadian bio-tech company that he helped take public and sell for nearly $200 million.

Mr. Jennings holds a BS from the University of Manitoba and sits on several committees that explore the clinical benefits of medicinal marijuana for children.

Jonathon Rennie, PhD

Director of Cannabinoid Research

Dr. Jonathon Rennie, PhD, serves as our Director of Cannabinoid Research. Dr. Rennie is also an Adjunct Assistant Professor in the Department of Psychiatry at the McGill University, Montreal.

Prior to joining Genisis Biotech, he was a Research Health Science Specialist at the Canadian Centre on Substance Use and Addiction in Ottawa as well as sitting on the board at the National Center for Post-traumatic Stress Disorder, (PTSD), at The Life Line Canada Foundation. He is also the former Executive Director at the Institute for Research on Cannabinoids, (IROC), in Colorado Springs, Colorado.

As an early research pioneer of marijuana comorbidity, Dr. Rennie has spent over a decade investigating the interrelations between marijuana and a number of health conditions, including chronic pain, HIV, PTSD, and sleep disorders for the purposes of treatment development and refinement. His research has spanned from laboratory-controlled to clinical trials and pre-implementation. Dr. Rennie has published well over 100 peer-reviewed empirical publications, and he serves on the editorial boards of six scientific journals.

Dr. Rennie earned a BA in psychology and PhD in clinical psychology from the University of Toronto and has also completed a pre-doctoral clinical psychology internship at the Memorial University of Newfoundland and a joint postdoctoral fellowship at the Calgary Clinical Psychology institute.

Simon Hoffer

Commercial Director

Simon Hoffer has served as Genisis Biotech’s Commercial Director for nearly 7 years. Over his 25-year career in the pharmaceutical industry, Mr. Hoffer has held several leadership roles in marketing, sales, business development, analytics and alliance management.

Prior to Genisis Biotech, he was Director for Strategic Portfolio Management at Cipher Pharmaceuticals, a publicly-traded, Canadian-based dermatology company, where he managed the company’s global portfolio.

Mr. Hoffer also held various roles of increasing responsibility at a Montreal-based specialty bio-pharmaceutical company. In his last role as Executive Director, Corporate Development & Licensing with them, he participated in several transformational M&A, licensing and co-promotion deals through, and including, several international acquisitions.

Mr. Hoffer held senior managerial positions at several bio-science companies during the initial commercial build-out of the organization and spent over a decade at GlaxoSmithKline in various U.S. and global commercial roles within specialty markets, including the marketing of treatments for neurological conditions and epilepsy.

Mr. Hoffer received a B.A. double major in Political Science/Policy and Management Studies from Dickinson College in Carlisle, Pennsylvania.

About Us

Genisis Biotechnologies, as the company is today, was formed in 2012, and since then we’ve invested in the continuous growth of our research and development, our people and our products. We’re committed to improving the quality of life for patients worldwide. This means we also work hand in hand with healthcare providers and industry organizations to support continued research and education programs which provide safe and effective products.

Our facilities located in Calgary, Ontario were designed to ensure that our research and development is performed within a strict clinically safe environment. We also ensure that all of our products are manufactured and delivered to patients in their best state. We strive to achieve that medicinal marijuana should be available to every patient that needs it, worldwide.

Genisis Biotechnologies produces industry-leading research and development which allows for the delivery of superior marijuana-based health care products to patients. Genisis Biotechnologies leads the industry across diverse disciplines.

Through our strategic partnerships we are now involved with all of the steps necessary to get our clinically approved products to patients. We take a scientific approach to all of our product development and believe that, despite this attention to detail, medicinal marijuana shouldn’t be costly, inconsistent, or difficult to access.

Genisis Biotechnologies is actively acquiring, or joint venturing, with companies across all sectors of the medical marijuana industry in an effort to build a ‘research-to-sales’ portfolio of complementary companies and joint venture partners. We are committed to providing pharmaceutical-grade medicinal marijuana and superior patient care, while balancing patient economics and returns to shareholders.

Our dedicated team of professionals and partners will always ensure a high-quality product and purity before moving through to production and finally to the point of shipment. Our products are now being sent to dispensaries worldwide, including several dispensaries owned and operated by our partners and shareholders.

There is a perfect storm on the horizon for the medicinal marijuana industry, as there is a significant economic need for increased patient care in most countries around the world, along with a strong demand for ongoing research and development. Medicinal marijuana is now clinically proven to provide effective medicines, without side effects, for the treatment of chronic pain and conditions.

Dedicated to a patients’ progressive healing, we aim to broaden the understanding of medical marijuana and its therapeutic properties to the medical profession and help meet chronic disease patients’ ongoing needs with customized products. We’re proud to be part of an industry that’s helping patients worldwide to access better medicine; and as we grow, we will continue to provide patients with reliable access to safe, consistent, and effective medicinal marijuana treatments and cures.

Patient comfort and safety and healing are Genisis Biotechnologies’ daily drivers. Regular improvements to our research facilities, product testing and growing methodologies mean we’re able to produce safe, effective and high-quality medical marijuana for our patients, time and time again.

One of our main goals is to help build a global medical marijuana brand that’s dependable with therapeutic claims proven and backed up. Through education, research, and development, we will develop and change the cultivation and science of medically authorized marijuana for the better. By developing this new industry by creating a natural product from research-to seed-to sales, we are helping our patients live the life they deserve.

Philosophy

Dedicated Research - Clinically Proven Cures - Unquestionable Ethics

We strive to achieve a safer, more curable future through continuous and dedicated research and development and to ensure the availability of the most clinically proven products for patients worldwide. Patient comfort, safety, and cure are the drivers of our success at Genisis Biotechnologies. Lead by our medical professionals’ leadership team, Genisis Biotechnologies is advancing as a fast-growing medical marijuana company engaged in cutting-edge innovation, research, and development that will strengthen the science of medicinal marijuana for generations to come.

A healthier future through sustainable business strategies. Genisis Biotechnologies are providers of advanced research for medicinal marijuana. We work hand in hand with our partners who cultivate and grow high quality marijuana to help us develop therapies and medicines that will improve the way of treatments for those difficult to cure diseases. Our partners, whom we work with hand in hand, help us to deliver finished products that are derived from our research and development programs. By producing products that are recognized as effective treatment to diseases, we are aiming to be one of the leaders in developing and improving the way the world cures illnesses.

With medical science moving into a new technology, our company’s mission is to enable each person to have access to medicinal-grade marijuana for the improvement of their overall health, and possibly to eradicate illnesses that are hard to cure. For us to be able to reach this goal, we participate in clinical trials that differentiate and compare our current findings to other leading medicinal marijuana companies which improves our own in-house research and development of new medicines.

We also believe that proper education will enable all cultures to understand how this plant can improve their way of living. We do this by working with many non-profit organizations that educate and perform medical treatments to different parts of the world. We are aiming for the world to understand that with correct administration, medicinal marijuana will treat an ever-increasing number of conditions and illnesses with minimal to no side effects.



Mission and Vision

With an ethical integrity and a commitment to our patients in mind, we research, develop and produce clinically proven medicinal marijuana medication.

Our company’s mission is to empower patients and healthcare providers with a knowledge to understand and adopt medicinal marijuana as a medication that can help towards a community of health and well-being. Our purpose is to make a positive and meaningful experience in the lives of patients and their caregivers. All of our actions and decisions tie back to this most important fact. Equally, we want our employees, partners and investors to understand and trust that Genisis Biotechnologies and its partners are committed to doing the right thing. This is why we have made it clear what we expect from everyone associated with us.

We don’t only strive to follow best practices, we aim to set them by building and partnering with industry leading companies that are innovators and who will assist us with the promotion of marijuana as a clinically proven medicinal product that eliminates pain and heals chronic diseases that are considered incurable at this time and age. We also aim to responsibly elevate the consumer experience by providing medicinal marijuana products that are pure and of the highest quality. We make sure that only organic medical marijuana, in soil without the use of chemicals is used to reach a natural purity and achieve the maximum effects from the plant.

Our goal is to establish the most valuable international marijuana community comprised of passionate, daring people, driven by quality and integrity, who are determined to write history and change the world, not read about it.We’re committed to improving the quality of life of patients worldwide.

This means working hand in hand with healthcare providers and industry organizations, supporting research and education, and providing a safe, effective product. Our consumers’ trust is very important to us as this measures our success as an industry leader of medical marijuana, building an iconic portfolio that offers effective and quality therapeutic products on the market, while generating value for our shareholders.

Genisis Biotechnologies’ mission is rooted in unlocking the potential of cannabinoid medicines to address serious medical conditions with limited treatment options. Our efforts are guided by several fundamental principles. At all times we strive to be passionate to create the best product in our category, patient driven, innovative – to ensure that we provide our patients with the newest treatments and cures, all backed by research.

The Genisis Biotechnologies’ team collaborates with different bodies of education, learning and research so they can accomplish more through this strategic team work. We also instill accountability in everything that we do, to take responsibility and deliver on our commitments. In continuing to follow these values, we believe we can fulfill our mission to be the global leader in cannabinoid medicines, developing and providing pharmaceutical products which address clear unmet needs


Our Values

  • Transparency — Information is shared openly and clearly to allow for greater care to patient needs.
  • Communications – Our interaction with our partners, patients and shareholders are always respectful, honest, and forthright.
  • Passion - Our sense of passion in completing our work ensures the importance of delivering ground-breaking research when it’s needed.
  • Perseverance — Challenges, however difficult they may be, only strengthens our perseverance and persistence.

Our Research

Genisis Biotechnologies are dedicated to marijuana research and development. Our goal is to define the future of the medicinal marijuana industry by rigorous scientific research and development programs which help assess the safety and efficiency of marijuana and marijuana compounds for treating medical conditions.

We are strongly committed to our research programs which leads to an improved quality of life for patients in a time frame that matters. We partner with doctors, physicians, hospitals, clinics and universities to advance the clinical applications of medicinal marijuana. We conduct both clinical and pre-clinical research and development of medicinal marijuana to provide evidence one way or the other to answer the question, “Can Medicinal Marijuana cure hard to treat illnesses that is bothering the world today?”

We have developed a close working relationship with many state and federal agencies worldwide to help gain regulatory approvals and have assisted panels of nationally-recognized experts to assist with the rigorous processing of applications. Furthermore, we have funded carefully designed studies that have now been published in several scientific journals, and by doing so making significant contributions to the available literature on marijuana and cannabinoids. These results have helped bring together accomplished international experts on marijuana and cannabinoids and expand upon the possible uses of marijuana as a therapeutic agent to a number of chronic conditions.

The challenges that we encounter through our clinical trials and research programs are numerous, but despite them we remain committed to the improvement and advancement of medicinal marijuana’s clinical development. Much of our research team's efforts are focused on not only developing and studying marijuana's potential medicinal benefits, but also its potential risks.

We strive to give patients’ relief from their conditions and illnesses and give them control over their lives when they need it. Our research is focused on developing marijuana in to medicine that will treat a plethora of conditions. Through exhaustive development and clinical testing of marijuana and cannabinoid their medicinal qualities are now proven treatments for pain relief, control of nausea and vomiting, as well as appetite stimulation, to name a few. This proven testing has now further emphasized the need to develop safer and more effective methods of accurately administering these drugs to patients.

Genisis Biotechnologies conducts high quality scientific studies intended to ascertain the general medical safety and efficacy of marijuana products and examine alternative forms of medical marijuana treatments and administration. Because of this, we are now considered as a reliable resource to assist with health policy planning by virtue of our close collaboration with global marijuana producers and product developers. We value integrity and honesty, and our decisions are informed by research.

CBD and THC

For many years now, marijuana has been shown to positively treat an ever-growing number of medical conditions. For centuries, different forms of the plant have been used to treat many different conditions and symptoms. Marijuana has been used to relieve a myriad of symptoms and conditions including pain and anxiety, reduce inflammation, encourage sleep, and prevent seizures. Marijuana is one of the oldest and most versatile medicines in the world.

We are here to provide you with information on medicinal marijuana in a very straightforward and simple to understand way. Whether you are just beginning to explore the medicinal powers of marijuana, or have been self-medicating for years, clinical research now shows that marijuana is effective in providing benefits for people suffering from an increasing number of conditions and symptoms.

Current knowledge about marijuana's effects derives from three main sources: personal and historical accounts of its use, clinical studies, and scientific research of marijuana’s constituent compounds. Different compounds in marijuana have different actions in the human body.

Delta-9-tetrahydrocannabinol, (THC), the plant’s naturally found compound causes the ‘high’ reported by marijuana users. Cannabidiol, (CBD), has very little or no noticeable psychoactive effect on users and is the plant’s naturally found compound primary used in medicinal marijuana.



Tetrahydrocannabinol

Tetrahydrocannabinol, (THC), is an active chemical in marijuana and is one of the oldest psychoactive drugs known. Marijuana contains approximately 60 different strains of chemicals of which one of the most important is THC.

THC has several unique medical benefits. Its anti-emetic properties, which inhibits vomiting, are particularly useful in the treatment of cancer patients on chemotherapy to relieve pain and nausea and it is also proven to reduce inflammation. Furthermore, as THC increases the appetite and reduces the vomit response, it is starting to be used in the treatment of anorexia and other eating disorders.

Further anti-cancer properties of THC have also been recently discovered. This applies primarily to brain cancer cells. Clinical studies now show that THC, when mixed with CBD, is effective not only for cancer-symptom management, such as nausea, pain, loss of appetite, fatigue but for other conditions as well. Our research has shown that THC slows tumor growth in common lung cancer and significantly reduces the ability of the cancer to spread. THC selectively targets and destroys tumor cells while leaving healthy cells unharmed.

Compared to traditional toxic chemotherapy drugs available today, marijuana treatment is safer and just as effective. Our own clinical research matches that of the medical science industry, that THC has proven anti-tumoral properties and is now increasingly recognized and accepted as a seminal advancement in cancer therapeutics.

Cannabinoids

Cannabinoid, (CBD), is a non-psychoactive cannabinoid found in marijuana plants and is credited for several pharmacological properties. It is also known to have beneficial effects against inflammation, pain, neurological conditions, cancer, and other ailments.

CBDs are now clinically proven to provide such medical efficacy to humans because they mimic our own naturally produced endocannabinoids, and bind to the same receptors, located throughout the brain and body. The human endocannabinoid system is responsible for regulating many different body systems, including pain, memory, mood and appetite. The unique ability of cannabinoids to be able to communicate with the human body in the same manner that it communicates with itself makes it an ideal medicine for humans.

Translating into medicinally valuable relief, cannabinoids have been successfully used in the treatment of conditions such as cancer, seizures, and Parkinson’s disease and symptoms such as inflammation, pain and assisting sufferers of Hepatis C and HIV to manage their conditions far better than ever before.Cannabinoids’ ability to act on the body’s cannabinoid receptors help promote the body’s healthy regulation of the central nervous, immune, and endocannabinoid systems.

Patients are increasingly now relying solely on CBD, instead of conventional medical care, as treatment for numerous physical illnesses and conditions. This is why our company is continually researching and developing products and medicines that are clinically proven for human consumption. Our research goal is to ultimately create a brand that produces medicinal marijuana products that will heighten the effectiveness in curing conditions that have been proven to be difficult to cure by conventional medicine alone.


Clinical Research Focus

Medicinal marijuana research and development is where our main focus lies and is one of the most ground-breaking technologies of benefit to the medical industry today. After years of research and development only now has medicinal marijuana been welcomed with open arms by all branches of the medical profession.

Traditionally, marijuana was only considered as a recreational drug, however with the help of clinical research facilities such as ours, the world has been introduced to alternative ways in treating specific, and more importantly, hard to cure conditions that have been a challenge to the medical world for many centuries.

Our company is considered as an integral part to this global ground-breaking movement where marijuana can be considered as a strong alternative to the toxic treatments that are more readily available to patients today. We are not only here to further develop marijuana-based products, but to also introduce and educate the general medical audience to the realities and possibilities that medicinal marijuana can now offer humanity for the purpose of treating chronic Illnesses.

Our focus is on giving doctors and patients the one thing they want the most; treatment for their medical conditions and lives through the use of clinically proven medicines.

A. Oncology

The medical community along with an ever-increasing number of states and countries now recognize marijuana as a treatment for certain cancers and cancer-related symptoms, such as poor appetite, pain and nausea. According to recent surveys, the majority of patients with cancer now initiate conversations with their doctors about using medical marijuana as an alternative treatment and that over 80% of oncologists now discuss medical marijuana use with their patients.

Medical marijuana is now increasingly being used for the relief of symptoms related to cancer and we now see how medical marijuana can help patients alleviate their cancer-related symptoms like pain, nausea and decreased appetite. Research has also proven that marijuana can reduce the size of certain cancer cells.

The use of medicinal marijuana in oncology is now becoming more widespread, and with this increased use and acceptance our research continues to find ways to further improve medical treatments that are more effective and efficient in the treatment of cancer, and in the future, maybe even cure this deadly disease.

Our clinical trials will always be followed up with detailed reviews from patients after they are prescribed our marijuana treatments so we can observe how effective the treatments are to them, and also to see how we can improve the product in any way that we can.

B. Virology

The ever-increasing risk of resistance by the human body to conventional medicines, combined with the high cost of current therapies, makes it a necessity for cost-effective virological therapeutics to be discovered and developed. The recent demand for research in to virological medicinal marijuana has led to considerable findings in evaluating and validating its clinical and metabolite potential of curing various viruses and diseases. According to our own research and our numerous partner studies, marijuana now helps combat many bodily viruses and helps block the spread of them also.

Viruses can remain dormant for long periods within white blood cells before they burst out and begin replicating. These include gamma viruses, which includes Kaposi's sarcoma, which is associated with an increased risk of cancer that is particularly prevalent in AIDS sufferers. Another is Epstein-Barr virus, which predisposes infected individuals to cancers such as Burkitt's lymphoma and Hodgkin's disease.

Further to this, viral hepatitis B and hepatitis C pose a major health problem globally and if untreated both viruses lead to severe liver damage resulting in liver cirrhosis and cancer. While hepatitis B has a vaccine, hepatitis C has none at the moment which one of the driving factors behind why we are currently researching a marijuana-based cure for it.

Preliminary screening of CBD has revealed that certain strains are now clinically proven to assist with the spreading of hepatitis C but not so much against the spread of hepatitis B. These findings suggest that CBD could be further developed and used therapeutically against hepatitis C whilst our ongoing research in to hepatitis B continues.

C. General Medicine

Medicinal marijuana, as a clinical therapy, has garnered much global attention in recent years, and rightly so.Endocannabinoids, (eCBs), and their receptors are found throughout the human body included in the nervous system, internal organs, connective tissues, glands, and immune cells. The eCB system has a homeostatic role and has been characterized as the body’s “eat, sleep, relax, forget, and protect”.

Controlled clinical trials, designed to compare marijuana with existing treatments, have shown that marijuana provides superior healing for certain conditions than existing remedies and this will further assist it being made available to appropriate patients in far greater numbers. Here are some research backed studies that have been proven by our clinical research team and by our other partner where medicinal marijuana has been proven more effective than existing pharmaceutical treatments.

  • Glaucoma. Glaucoma increases the pressure in the eyeball, injuring the optic nerve and causing loss of vision. Medicinal marijuana lowers the pressure inside the eye and the effects of the drug can prevent blindness.
  • Cancer. Medicinal marijuana can slow and stop cells from spreading. According to a study, published in the journal Molecular Cancer Therapeutics, cannabidiol has the ability to stop cancer by turning off a gene called Id-1 and that marijuana actually works to considerately slow down tumor growth in brain, breast, and lungs.
  • Alzheimer’s disease. Medicinal marijuana’s naturally occurring THC, one of the main active ingredients present in marijuana slows the progression of Alzheimer’s disease.
  • Muscle spasms. Medicinal marijuana can control and calm the attacks of certain types of muscle spasms almost immediately by being able to relax the muscles of the diaphragm.
  • Improve lung health. Medicinal Marijuana can help reverse the carcinogen effects of tobacco, and improve lung health. In January 2012, a study published in Journal of the American Medical Association showed that marijuana improves lung functions, and even increased lung capacity. Researchers looking for risk factors of heart disease. Tested on 5,115 young adults, over the period of 20 years, the research found that only those that smoked marijuana showed an increase in lung capacity, compared to the tobacco smokers who lost lung function.
  • Arthritis. Research has shown that medicinal marijuana can relieve arthritis and also reduces pain and inflammation, and promotes sleep, which considerably helps with the discomfort experienced by people with rheumatoid arthritis.
  • Parkinson’s disease. Medicinal marijuana can soothe tremors for people with Parkinson’s disease. Recent studies that we oversaw in Israel shows that marijuana remarkably reduces pains and tremors and improves sleep for Parkinson’s disease patients. Furthermore, the research clearly showed an improvement of the patients’ fine motor skills among patients.
  • Epileptic seizures. A 2003 clinical study showed that marijuana use can control epileptic seizures. The study showed that THC controlled the seizures by binding the brain cells responsible for controlling excitability and regulating relaxation. The results were published in the Journal of Pharmacology and Experimental Therapeutics.
  • Multiple sclerosis. Medicinal marijuana has been proven to ease the pain of multiple sclerosis. Marijuana works to stop the negative neurological effects and muscle spasms caused by this debilitating disease.
  • Crohn’s disease. A recent clinical study conducted by our research team and a U.S. partner showed that a treatment comprising of both CBD and THC considerably reduced Crohn’s disease symptoms in 10 out of 11 patients, and caused a complete cancellation of the disease in five of those patients.
  • Hepatitis C. Medicinal marijuana can increase treatment effectiveness and lessen the side effects patients suffer with conventional medicines. The side effects, ranging from fatigue, nausea, muscle pains, loss of appetite and depression, are so severe without the aid of medicinal marijuana that many people are unable to continue their treatment.
  • Anxiety. Medicinal Marijuana is clinically proven to decrease anxiety in some of the most severe cases, including PTSD, panic attacks, phobias and obsessive-compulsive disorder.
  • Systemic Lupus Erythematosus. Lupus is an autoimmune disorder which medicinal marijuana is increasingly being used to treat this autoimmune disorder which occurs when the body starts attacking itself for unknown reasons.
  • Medicinal Marijuana can protect the brain after a stroke. There is quantifiable research that has shown neuroprotective effects from marijuana. Research now shows that the plant also helps protect the brain after other traumatic events like concussions.

INVESTOR RELATIONS

Our Investors and shareholders are the force of our persistence and success in the company. In conjunction with our research and development programs we offer solutions and partnerships to companies that range from the sourcing of raw materials through to the production of medicinal marijuana products. Our industry expertise creates business partnerships, business infrastructures and operational best practices to secure our company's stability and ensure its steady growth over the years to come.

Global spending on medical marijuana is now forecast to grow by over 300% a year over the next several years by virtue of more states and countries granting legislation of medicinal marijuana, increasing its worldwide access to patients and with this increased investor interest.We engage with institutional and retail investors from all 4 corners of the world and hold regular briefings and meetings with investment and financial analysts, during which they are given access to senior management.

Genisis Biotechnologies’ local and foreign institutional investors and overseas-based shareholders from Asia, Europe and the U.S. are constantly updated in relation to our ongoing corporate objectives, including long-term goals and financial targets. In addition, the Investor Relations’ Unit, together with senior management, regularly attend investor conferences and trade shows to further promote our company’s increasing sector presence.

We are currently undertaking 3 rounds of private placement funding to facilitate our listing on the New York Stock Exchange, (NYSE), before the end of the 3rd quarter of 2019. Anyone interested in becoming part of our success story before our much-anticipated flotation are advised that WFE Capital are the appointed brokerage over-seeing this development stage of our company’s growth and can be contacted via info@wfecapital.com.

For non-Investor Relations related inquiries please use the form on our Contact Us page.

Richard Powell,
Investor Relations Officer,
Genisis Biotechnologies.
richard.powell@genisisbiotech.com,
+1 587 997 1524

Press Releases

Genisis Biotechnologies also provides up-to-date information on breaking news for its patients, partners, shareholders and the media.

Genisis Biotechnologies Confirm Research For Marijuana-Based Treatment To Treat Epilepsy Nearing Completion For FDA Approval.

July 19th, 2019

July 19th, 2019

Genisis Biotechnologies have recently announced that their company’s internal research program for the marijuana-based treatment epilepsy and its associated seizures is nearing completion for submission to the FDA for approval.

The Calgary based company confirmed that their 2 year-long research and development program was at the final stages and will soon be submitted to the FDA for their approval under the name of Genorplexan.

Once granted, Genorplexan will be only the second FDA approved marijuana-based drug on the market, the other being Epidiolex which was granted FDA approval last year. As a result, since the launch of Epidiolex, the company behind it, GW Pharmaceuticals, a UK-based company, have seen their stock value increase by nearly 50%, from just over U.S. $120 per share before its approval, to over U.S. $170 per share to date.

Genisis Biotechnologies, who are due to float on the New York Stock Exchange, (NYSE), later this year, are wanting to ensure that their true market value is realized as quickly as possible and consider the launch of Genorplexan to ensure that this is realized as quickly as possible.

“Our company’s philosophy has always been focused towards the medicinal benefits of marijuana-based treatments and cures, whether they be for the treatment of severe clinical conditions or mild pain relief, we have always focused on this sector,” said Drew Lancaster, Ph.D., Head of Product Development with Genisis Biotechnologies.

“Ensuring Genorplexan gets to market quickly once FDA approval is granted will allow us to take full advantage of the North American marketplace for the treatment to the millions of seizure and epilepsy sufferers who depend upon such a drug to keep their conditions well-medicated and under control,” Lancaster added.

“Furthermore, our research team are also nearing completion on two other medications that we will be presenting to the FDA for approval late this year and early next year. Currently, neither of these medicines have yet had any other company approach the FDA for approval which will further establish us as a market leader in the medicinal marijuana sector,” Lancaster concluded.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies Announces International Medical Marijuana Research Expansion Program Strategy.

July 1st, 2019

July 1st, 2019

Genisis Biotechnologies, a Calgary based company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies utilizing marijuana for treatments as used by the healthcare industry, is pleased to announce the launch of an international expansion strategy to broaden its reach through its medical marijuana initiatives.

As more countries legalize medicinal marijuana, Genisis Biotechnologies will be focusing on partnerships allowing for their comprehensive Clinically Formulated Medical Record, (CFMR), platform with its medical marijuana software integration for education, decision support, and the prescription of medical marijuana to private companies and government departments in fast-growing markets such as the U.S., the UK and Australia.

The legalization of medical marijuana is projected to boost the demand for marijuana for medical use as a substitute for traditional pharmaceutical medicines. Approximately 30 countries have already legalized medical marijuana in some capacity, as well as a others that allow its use within strict guidelines, such as in the form of marijuana -derived pharmaceuticals.

According to a report by Zion Market Research, the global medical marijuana market was valued at approximately U.S. $13 billion in 2017 and is expected to generate revenue of around U.S. $50 billion by the end of 2024. In addition, and as confirmation of Zion Market Research’s figures, P&S Market Research project the sector to attain a size of $30.4 billion by 2023.

The role of marijuana in treating medical conditions is continuously expanding to help patients with acute and chronic symptoms. Currently, there is a critical gap between the patient’s need for medical marijuana, and the physician’s comfort and knowledge to prescribe it. This knowledge gap is even more widespread in countries that are behind Canada in its adoption of medical marijuana and where this program will be most advantageous.

In addition, research into the safety and efficacy of marijuana by companies outside of Canada has traditionally been very difficult. Genisis Biotechnologies is looking to fill that gap by allowing for access to their clinically led, evidence-based data which will be embedded directly in their CFMR software to help guide doctors to the appropriate medical marijuana product and dosing. The software will be further tailored to the regulatory and approval procedures associated with the different jurisdictions.

“With the increasing awareness and demand from patients around the use of medical marijuana, we are aiming to provide the best possible information and appropriate tools to physicians and authorities so they can make informed decisions about their patients’ health,” said Martin Milligan, PharmD, Director of Medical Services at Genisis Biotechnologies.

“As a pioneer in the space, Canada is at the forefront of this changing landscape. Our focus will be to bring credible physician-backed marijuana education to primary care physicians, where knowing your patient is an essential element of practice. Additionally, by innovating and integrating these increasingly in demand capabilities, Genisis Biotechnologies will be equipped to significantly increase its market share of the 30 billion Dollar plus medicinal marijuana market,” Milligan added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies Wish Mike Tyson And His Team Every Success With Their New 407-Acre Marijuana Holiday Resort In California.

June 13th, 2019

June 13th, 2019

Genisis Biotechnologies would like to wish Mike Tyson and his team every success with their new 407-acre marijuana-themed holiday resort in California which they will be calling “the Lollapalooza of cannabis”.

The ring legend, 52, started his own company called Tyson Holistic Holdings which Genisis Biotechnologies were responsible for much of the research and development involving the development of their hemp-infused product range earlier this year.

Iron Mike is now taking advantage of the state's legalization of recreational marijuana and has also started to run the Tyson Cultivation School which has been formed to help teach farmers how to grow and develop their strains.

But now the former ‘Baddest man on the planet’ plans to open his very own 407-acre weed holiday resort that will have a music festival and a specially designed ‘lazy river’ for his guests to relax on.

“I thought about how much good I could do by helping people with cannabis,” Tyson said.

Tyson and his business partner, Rob Hickman, refer to the new holiday resort as “the Lollapalooza of cannabis.”

The resort aims to help people understand the health benefits of marijuana, enjoy the drug on site and listen to live music.

Tyson told Cannabis Tech Today: “I thought about how much good I could do by helping people with cannabis. It was a no-brainer. I've been fighting for over 20 years, and my body has a lot of wear and tear.”

"I had two surgeries and I used marijuana to calm my nerves, and it would take the pain away. But before, they had me on those opiates, and those opiates had me all screwed up,” Tyson added.

Tyson’s business partner Rob Hickman said: “He's building a holistic center for health and wellness.”

"There will be testing in the university. It's going to be about educating people on the healing benefits, how to grow, and how to be in proper business," Hickman added.

“Our involvement with the Tyson Ranch earlier this year provided us with a great opportunity to apply our research and technology to their holistic products. Mike and Rob have developed and created a truly unique understanding of the marijuana market and we are pleased to have leveraged our skill sets with theirs,” said Drew Lancaster, Ph.D., Head of Product Development with Genisis Biotechnologies.

“We wish them every success with their latest project and look forward to extending our services further to them over the coming months,” Lancaster added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies Confirm 2-Year Partnership To Create CBD Oil Extraction Facility In California

June 4th, 2019

June 4th, 2019

Genisis Biotechnologies have recently announced that they have entered in to a 2-year partnership with an Oregon based medical marijuana company to create a CBD oil extraction facility in California, U.S.

Demand for smokeless products continues to increase and has been a driving force behind the demand for cannabis oil. These products are created with cannabis oil and have been found to possess tremendous health benefits and this has also made such products attractive to consumers, especially the older consumers.

“The demand for cannabis oils, especially high-quality CBD oil, continues to increase and this is a trend we expect to continue as our research finds more clinical benefits and therapeutic values that cannabinoids provide. Over the next few years, we expect this trend to become even more significant and consider this to be a very lucrative opportunity,” said Jonathon Rennie, PhD, Director of Cannabinoid Research of Genisis Biotechnologies.

During the last decade, the amount of people smoking cigarettes has significantly decreased while the number of people using e-cigarettes has skyrocketed. The trend in the cannabis industry is very similar, and the legal marijuana industry is in the middle of a major transformation where smoking CBD will be replaced by a capsule, a drink, or a vape pen.

“The ability to absorb CBD in to the blood stream without smoking will create significant opportunities for companies focused on producing cannabis oils. We are very bullish on the smokeless product market and have been focused on finding companies that are levered to this,” Rennie added.

Genisis Biotechnologies anticipate the new facility will be fully-operational within 4 months and will advise on further developments when they become available.

Both companies are also currently working towards creating a distribution center to support the manufacturing plant’s extraction process. The facility is to be located very close to the manufacturing facility and is to be approximately 7,800 square feet.

This will allow for the immediate and timely shipping of the CBD extracted oils which will ensure both companies gain an enormous market advantage over all other CBD extraction companies.

Once initial production commences, it is believed that production and supply of over 70,000 grams per week will be possible. The companies anticipate that production capabilities will be increased to over 100,000 grams per week within the first 12 months and expect this figure to grow further as their production facilities increase.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies Appoints Philip Maloney As Strategic Advisor To Explore Market Sector Partnerships For Expansion Strategy

June 1st, 2019

June 1st, 2019

Genisis Biotechnologies today announced that it has appointed Philip Maloney as a Strategic Advisor. Mr. Maloney and Genisis Biotechnologies will work collaboratively and strategically to explore potential partnerships that would be the optimal strategic fit for successful entry into each of Genisis Biotechnologies' contemplated market segments. Mr. Maloney will also advise on the company's research and product expansion strategy.

“Philip is a globally recognized business visionary with a strong track record of constructive engagement to generate accelerated, profitable growth and shareholder value across many industry verticals that are of great interest to us," said Clive Mendelson, Chief Executive Officer at Genisis Biotechnologies.

"Like us, Philip also takes a long-term view of value creation to benefit all stakeholders. We look forward to working with Philip to further extend our global marijuana industry leadership by aligning Genisis Biotechnologies with each of the major market segments cannabis is set to impact," Mendelson added.

"I believe Genisis Biotechnologies has a solid execution track record, is strongly differentiated from its peers, has achieved integration throughout the value chain and is poised to go to the next level across a range of industry verticals. I also believe that Canadian licensed producers, and Genisis Biotechnologies in particular, are well positioned to lead in the development of the international marijuana industry as regulations evolve, with a strong, globally replicable operating model,” said Mr. Maloney.

“I look forward to working with Clive and the extended Genisis team to evaluate its many operational and strategic opportunities, including potential engagement with mature players in consumer and other market segments," Mr. Maloney added.

In consideration for the services to be provided by Mr. Maloney Genisis Biotechnologies has granted Mr. Maloney the option to purchase 250,000 common shares in Genisis Biotechnologies at a preferred price of U.S. $0.85 per share over a four-year period subject the occurrence of certain specified events, which include the consummation of certain defined transactions and the current price of Genisis Biotechnologies’ common shares being at least U.S. $1.25 for a specified number of trading days.

Genisis Biotechnologies has granted Mr. Maloney registration rights relating to the common shares to be acquired through the exercise of the option period.

One of Mr. Maloney’s first responsibilities will be to oversee the company’s planned submission for approval to the FDA for their marijuana-based drug to assist with the symptoms of PTSD.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Medical Marijuana Based Treatment For PTSD Reportedly Nearing Completion For Submission To FDA For Approval

May 20th, 2019

May 20th, 2019

A medical marijuana-based treatment for PTSD, which has been independently researched and developed by Genisis Biotechnologies, is reportedly now nearing completion before being submitted to the FDA approval.

The drug, which has yet to be given a market name, has been specifically developed by the company using a unique combination of CBD strains along with a small amount of TCH in its formula to assist with the symptoms that sufferers of PTSD experience.

This will be only the second marijuana-based drug that the FDA have approved following their approval of Epidolex in June last year, which is a marijuana derived drug, developed by GW Pharmaceuticals in the UK, and used in the treatment of epilepsy.

Up until recently, PTSD had been poorly understood and had gone by a number of different names over the years. Dating as far back as World War 1 when it was called ‘shell shock’ and afflicted soldiers were simply told to ‘pull themselves together.’

PTSD is commonly only associated with military personnel although the American Psychiatric Association, (ACA), has now proven that police officers, firemen, ambulance operatives are also very susceptible to PTSD too. Furthermore, now that it is acknowledged to be a clinical condition it is also something that affects many other people with seemingly ‘normal’ lives.

PTSD is caused by a lack of anandamide, which is an endogenous cannabinoid compound which triggers the same receptors activated by THC and other marijuana plant components. After a traumatic event, the body doesn’t produce enough to fill receptor sites. When a PTSD sufferer uses marijuana, they replenish the all-important endocannabinoid, bringing them relief from their memories without any unwanted side effects.

“In 2016 the DEA gave formal approval to allow controlled clinical studies to show the effect of marijuana medication on veterans with PTSD. Since then it has been a key area of our research and development focus as conventional medication failed to address the condition’s many unmet needs,” said Drew Lancaster, Ph.D., Head of Product Development at Genisis Biotechnologies, Calgary.

“Certain conventional medicines will always struggle to replace certain naturally occurring chemicals that the body produces, which is where marijuana-based treatments benefit the patient the most,” Lancaster added.

“The exact composition of the CBD strains and THC components used in the medication were arrived at following years of exhaustive research and clinical trials. The many benefits include the prevention of unwanted memories from surfacing, insomnia and anxiety, all of which are primary symptoms associated with the trauma. We are extremely confident that the FDA will not only recognize the benefits this medication affords the sufferer but also give it their approval for use in the near future,” Lancaster concluded.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies In Early Talks To Develop Partnership With Prestigious Medical Marijuana Propagation And Cultivation Company

May 2nd, 2019

May 2nd, 2019

Genisis Biotechnologies have recently announced that they are now in early-stage talks to partner one of Canada’s most specialized and prestigious medical marijuana propagation and cultivation companies.

The partnership is reportedly expected to happen within the next few months with both parties already in agreement with the fundamentals and financials of the deal. Currently several non-disclosure agreements are in place with regard to the company concerned and full disclosures will be made immediately upon the partnership being confirmed, although most market analysts have been aware of the initial discussions for some time it is only now that Genisis Biotechnologies have confirmed the acquisition.

“We purposely delayed the release of the news relating to this impending acquisition as it was important that both parties were at an advanced point of the discussions. We are now at that point and expect everything to be agreed within the next few months,” said Don Jennings, Director of Corporate Development at Genisis Biotechnologies.

“This acquisition will allow us to further advance our in-house research and development facilities and will ensure that we continue to put the well-being of medical marijuana users, and the benefits that they receive from it, as our primary responsibility,” Jennings added. This news has been viewed as extremely positive by many market analysts who see it now coinciding with Genisis Biotechnologies’ impending flotation.

“This recent move will very quickly ensure that Genisis Biotechnologies solidify their position as one of sector’s main players and will add further investor interest in relation to their current IPO. Such announcements make their launch act like a tightly coiled spring, and with every announcement made between now and flotation these announcements are adding more and more value to a company, that in our eyes, is currently under-valued,” said Patrick Marsh, a senior market analyst with HSBC, Hong Kong.

Further acquisitions and mergers are now expected as the company nears flotation as their market value increases in conjunction with their market share.

“It is our intention to continue with the company’s expansion to ensure the advancement of clinical care to the medical industry worldwide. Whether this be via vertical growth or acquisitions and mergers, it will only be undertaken with companies that we know will be a perfect fit to our established approach and philosophy,” Jennings concluded.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies In Discussions To Acquire German Pharmaceutical Distributor With $150 Million In Annual Sales Revenue

April 23rd, 2019

April 23rd, 2019

Genisis Biotechnologies today announced its proposed acquisition of a leading distributor of pharmaceutical products to more than 11,000 pharmacies in Germany. The transaction, when closed, will strengthen the company's end-to-end medicinal marijuana operations and infrastructure in Germany, a key market in Genisis Biotechnologies’ international expansion.

"This acquisition strengthens our foothold in Germany, one of the most highly sought-after medical marijuana markets in the world," said Don Jennings, Director of Corporate Development at Genisis Biotechnologies.

"The company are cash-flow positive and has significant experience with regulatory requirements and international logistics. It will be a strong addition to our presence in Germany, providing deeper access to the important pharmacist channel and advancing our ambitious global growth strategy,” Don Jennings added.

Founded in 2002, the company, who until the deal is finalized have requested anonymity, is a leading importer and distributor of EU-pharmaceuticals for the German market, with over €100 million in annual revenue. Upon finalization of the deal, Genisis Biotechnologies will then announce a supply agreement with the German company to export approximately 1,200 kilograms of medical marijuana products from Canada to Germany.

"We are pleased to join forces with a premier global medicinal marijuana company, whose commitment to quality, safety and patient care closely aligns with our own. This is an exciting opportunity to build on our established network and advance our participation in a rapidly growing, emerging industry," said a spokesman for the German company.

The transaction will bolster Genisis Biotechnologies’ growing presence in Germany, which includes a three-pronged approach covering demand, supply and distribution. Earlier this year the company acquired a stake-holding in Berlin-based institute that provides access to both doctors and patients to support education about the benefits of medical cannabinoids.

"We are focused on leading the way in the medical marijuana market in Germany and by combining Genisis Biotechnologies’ expertise with an established local market presence, we are well positioned to continue on that journey," Don Jennings added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies To Assist With Multiple Patents For Marijuana-Infused Single-Serve Coffee Capsules

April 15th, 2019

April 15th, 2019

Genisis Biotechnologies have recently announced that they are to assist with the passing of multiple patents for marijuana-infused single-serve coffee capsules.

The company has entered in to a non-disclosure partnership and will be assisting with several patents to allow for caffeine-based products to enter into the marijuana-infused beverage market with single-serve coffee and beverage pod products. These patents will result in allowing products that brew marijuana-infused coffee, tea and cocoa to be manufactured and sold at retail stores.

Initially the patents have been applied for in the U.S. only although it is expected that once granted worldwide patents will be applied for allowing for products featuring cannabinoids, (CBD), in single-serve capsules and pods.

This single-serve capsule market is worth over U.S. $4 billion a year in the U.S. alone and a recent study showed that nearly 50% of Americans now own, or use, single-serve coffee making machines. The growing consumer appeal for this product has now been forecast for it to reach an estimated U.S. $8 billion in retail sales by 2022, and in doing so will be bigger than the traditional flower sales market.

Securing such patent partnerships is a great foundation for Genisis Biotechnologies to enter in to the marijuana-infused single-serve beverage industry and will be complementary to their other beverage related cannabinoid products. The company also expect to see further substantial development potential of new revenue streams through assisting with other licensing infused coffee and tea brands via strategic partnerships.

“Our research teams have worked tirelessly and have developed several specific CBD formulas which are not only 100% water soluble but also tasteless at the same time, both of these pre-requisites are necessary to ensure the taste of the beverage is not affected in any way by the consumer,” said Drew Lancaster, Ph.D., Head of Product Development with Genisis Biotechnologies, Calgary.

“Further research is ongoing and we are developing even more formulas that are suitable for use as additives to marijuana-infused beverages, both hot and cold and we look forward to assisting with several other companies as they look to develop their own unique marijuana-infused beverage ranges,” Lancaster added.

“Having worked with several successful marijuana companies in the past, we are extremely pleased to close a deal with Genisis Biotechnologies. They have perfected their craft, and strategically identified new markets for targeted growth. I look forward to us working closely with them and cementing ourselves with them at the top of the industry as a trusted manufacturer of premium quality marijuana-infused products,” said a spokesman for the partnering company.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain. For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies Expands Management Team To Support Future Strategic Initiatives And Partnerships

April 10th, 2019

April 10th, 2019

Genisis Biotechnologies today announced that the company has appointed Martin Lomas as its Director of Corporate Development and Strategy. In this newly created role, reporting to the Clive Mendelson, Chief Executive Officer, Mr. Lomas, in collaboration with senior executives across the company, will focus on the company’s global growth and partnership strategies and investor development.

Mr. Lomas comes to Genisis Biotechnologies with global investment banking experience, having most recently served as Managing Director of an equity-linked investment capital company. In this role, he successfully led the financing for a number of issuers, including several marijuana companies who recently offered investors convertible notes offerings. Mr. Lomas received a B.Sc from the University of British Columbia as well as an MBA from the Rotman School of Management at the University of Toronto.

“With deep experience in the U.S. and Canadian capital markets, Martin has already been a trusted independent advisor to Genisis Biotechnologies on a variety of growth initiatives, including our recently successful private placement program,” said Clive Mendelson, Chief Executive Officer of Genisis Biotechnologies.

“In this new position, Martin will be a core member of Genisis Biotechnologies’ senior management team, executing on the development of key strategic initiatives, including partnerships and M&A opportunities. We look forward to working closely with Martin to leverage his extensive knowledge in the execution of our investor development, international growth and partnership strategies, sourcing potential accretive opportunities in the global marijuana industry and negotiating favorable business transactions.”

Headquartered in Calgary, Canada and with partnership operations in 6 countries across three continents, Genisis Biotechnologies are slowly becoming one of the sector’s largest and leading marijuana companies. Genisis Biotechnologies are vertically integrated and horizontally diversified across every key segment of the value chain, from marijuana research and development, genetics research and high value-add product development.

Highly differentiated from its peers, Genisis Biotechnologies has established a uniquely advanced, consistent and efficient strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in high-quality product formulas.

Genisis Biotechnologies facility is built to meet EU GMP standards, and the companies that have established partnerships with have now also achieved this level of certification.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, Genisis Biotechnologies are distinguished by their reputation as a partner and employer of choice in the global marijuana sector, having invested in and established strategic partnerships with a range of leading innovators

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain. For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies Confirm Increased Research In To Marijuana-Based Treatments For Animals Following Approval

April 8th, 2019

Genisis Biotechnologies have confirmed that their research program in to marijuana-based treatments for animals will be increased significantly following approval from Veterinary Drug Directorate of Health Canada.

The primary focus of the research will be for the treatments of ‘companion animals’ although this program will also expand its research for the treatment of specific ailments in certain other animals.

Several Canadian marijuana companies have been positioning themselves to cash in on the drug’s potential for pets after the country’s legalization allowing for the recreational use of marijuana. Genisis Biotechnologies are now one of the front-runners of this market sector after their Health Canada approval for clinical research in to the use of cannabis-based products to treat animal anxiety.

The Canadian Veterinary Medical Association’s, (CVMA), Dr. Shane Renwick says, “We hope that there will now be the research required to allow safe registered products on the market in the not-too-distant future. It will offer alternatives in a lot of cases to medications we’re currently using for a variety of conditions. So, it’s an exciting potential that we see.”

There’s been a flurry of marijuana-related pet health research since Canada’s legalization allowing for the use of recreational marijuana was passed on October 17th and the association fully expect there will now be many more clinical trials approved for veterinarian research.

“The association is fully expecting that Health Canada will start to approve more and more marijuana-based veterinary health products that its members can prescribe for their pet clients, and each clinical trial approval brings them one step closer in the process,” Renwick added.

“The use of natural-occurring cannabinoids as a therapy for companion animals is a logical new forefront of medical discovery. These trial approvals mark a significant milestone on the journey of making marijuana-based drugs accepted and recommended by veterinarians,” said Drew Lancaster, Ph.D., Head of Product Development with Genisis Biotechnologies, Calgary, who are one of the companies that have already announced a clinical research program in to marijuana-based veterinarian sector treatments.

“Being able to develop a presence with the pet loving consumer will be a point of strength as there is already a huge demand for safe, tested marijuana-based products for pets. The CVMA has been advocating that veterinarians should have the same ability as medical physicians to prescribe them as well and we intend to provide the clinical research required to allow this to happen,” Lancaster added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

U.S. Federal Government Confirms: Marijuana Kills Cancer Cells Which Assists With The Cure & Treatment Of Brain Tumors

March 22nd, 2019

The U.S. Federal Government has recently admitted that marijuana serves as a useful treatment for brain tumors, one of the most dangerous type of cancers. And with this acknowledgement a re-classification of marijuana is now expected to allow for more U.S. companies to enter in to clinical research programs.

This stand by the Federal Government is said to be based on a major study by researchers at the St. George’s University of London that found that marijuana can be an effective drug to fight brain tumors.

The U.S. National Institute on Drug Abuse has said, “Recent studies have shown that marijuana can kill certain cancer cells and reduce the size of others. Evidence from one study suggests that extracts from whole-plant marijuana can shrink one of the most serious types of brain tumors. Research also showed that these extracts, when used in conjunction with radiation, further increased the cancer-killing effects.”

One of the lead researchers of the study, who made the discovery, explained that it is refreshing news that the U.S. government is looking to take a new stand on marijuana.

The new U.S.’s Surgeon General, Dr. Vivek Murthy, said, “I am optimistic that the U.S. government will now allow for clinical research to be carried out to fully explore the drug’s benefits, for the benefit of all people.”

“We already have some proven clinical data which clearly shows that with certain medical conditions and symptoms, marijuana can be helpful. We have to use that data to drive policy-making,” Murthy added.

The American Academy of Pediatrics, (AAP), has also adjusted its official position on marijuana and also called for the government to drop its Schedule 1 status in order to facilitate more research on its effects. Also, a bill was recently introduced in the Senate would reclassify marijuana to allow exploration of its medical benefits.

“This means that the hardline stand on marijuana is soon to be weakened. The government’s acknowledgement of the study augurs well for advocates for medical marijuana usage. The drug’s Schedule 1 classification has stifled scientific inquiry into the effects of marijuana and has resulted in a catch-22: Marijuana is labeled Schedule 1 because it’s assumed to have no medicinal benefits, but clinical trials have now proven this not to be the case, which means the government’s legislation will soon be changed,” said AAP CEO, Karen Remley.

“This news will soon ensure that medical marijuana’s proven clinical benefits will be available under prescription by considerably more people than it currently is,” said Sarah Blackwall, Ph.D., Director of Formulation Sciences at Genisis Biotechnologies, Calgary.

“We know from personal experience in Canada that once federal approval is given the research flood-gates open up as companies are permitted to pursue their independent research and development in to marijuana’s clinical benefits unhindered. Furthermore, it allows for a far greater understanding, at federal level, of the potential that medical marijuana affords the many sufferers of many conditions, most of which have unmet needs from conventional medicine. This will very quickly result in more and more federal agency approvals of marijuana-based medications, such as Epidolex, the first FDA approved marijuana-based medication used in the treatment of epilepsy, and Geniflexin, which is one of our own drugs soon to be presented for FDA approval which we developed in-house for use in the treatment of PTSD,” Blackwall added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Monsanto And Genisis Biotechnologies In Discussions To Develop Genetically Modified Marijuana To Specifically Target Leukemia

March 13th, 2019

Monsanto, the multi-billion agribusiness giant from St. Louis, Missouri announced on Friday that it is to enter in to discussions to form a partnership with Genisis Biotechnologies of Calgary to develop a genetically modified strain of marijuana specifically to target leukemia.

Should this potential partnership be forged between two of the leading companies involved with medical marijuana research and development they will apply for assistance and backing from Australia’s Department of Health who have voiced their interest to join in the venture following the passing of their recent legislation allowing for medical marijuana clinics to be opened.

The news has been welcomed by doctors, physicians, scientists and political leaders alike as a move forward towards the advancement of medical marijuana products for clinical use and is expected to bring a major shift towards medical marijuana policies throughout the world.

Earlier clinical research by Genisis Biotechnologies found that two certain cannabinoids proved to have anti-cancer effects when taken together. However, when these cannabinoids were paired with conventional chemotherapy drugs, that’s when the real benefits of CBD and THC became apparent. Patients who were administered these compounds after undergoing chemotherapy had their cancerous cells killed off far more efficiently and quicker.

Monsanto’s interest in this research has been interpreted by experts as the precursor to “a major shift in global medical marijuana policies” and it is believed the company would not have entered in to it if it did not have prior knowledge of the world’s government’s “openness” towards the eventual future blanket legalization of medical marijuana.

Lawyer and marijuana law specialist, Edmund Groensch, of the Drug Policy Alliance, admits, “The Australian Health Department’s potential involvement in this project will definitely help the pro-legalization globally.”

“A GM strain produced by a company with the credentials and prestige of Monsanto in conjunction with Genisis Biotechnologies’ cutting-edge research should be seen as ground-breaking within both the clinical world and the business world of medical marijuana” he added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotech To Develop Further CBD Oil Formulas As Patients Increasingly Turn To Vaping Medicinal Marijuana

March 1st, 2019

“Nobody smokes marijuana anymore, they vape it.” - New York Times

Vaping is now set to shake-up the booming medicinal marijuana industry. Despite vaping still being in early stages of development it is expected to offer one of the sector’s most explosive growth plays, particularly for patients using marijuana for medicinal purposes.

Traditionally, the smoking of marijuana was the dominant consumption method for recreational purposes. However, as CBD oils have been further developed, and vaping delivery techniques improved, vaping is now becoming popular for the administration of medicinal marijuana by an ever-growing number of patients due to its ability to deliver medication and relief immediately.

Alternative consumption methods, which includes vaping, only currently accounts for less than half of the market today. Although that's changing fast and the sector is now hitting a point where vape pens and marijuana extracts are starting to make up a huge share of the way in which marijuana is now consumed, both recreational and medicinal.

Similar to the tobacco industry. Smoking is in steady decline. Meanwhile, electronic cigarette smoking has soared, and the same conversion is set to sweep through the entire marijuana sector.

2019 is being forecast as the year that vaping marijuana will really take off and is set to take over a sizeable market share of the entire legal marijuana industry. Thereafter, the growth prospects are even higher and market data clearly shows the turning point for vaping marijuana is here now.

According to ArcView Research, vaping accounted for just $200 million of all legal marijuana sales in 2015 but has steadily increased since then and has grown in both total revenue and total market share within the sector.

From 2015 to 2018 the vape segment grew nearly six-fold to just over $1.1 billion. A huge growth over just three years but that is only the beginning.

The market share of vaping is now forecast to grow even more and ArcView projects record growth years indefinitely into the future for vaping as research and technological advancements continue.

By just next year, ArcView expects the vape segment of the legal marijuana industry to nearly quadruple to over nearly $4 billion, and with this, vaping’s market share of the entire industry will climb to nearly 25%. And by 2021 ArcView predicts vape sales will surge by another $2.3 billion to over $5.4 billion.

Analysts are now predicting that vaping will make up an ever-growing part of the legal marijuana industry. The reasons for the rise of vaping are many. Vapes can offer better taste, are more convenience, offer more portability, allow for varying levels of strength but most importantly they are able to now offer a precisely controlled dose, with immediate effect to patients. A fundamental transformation that has caught the interest of many investors.

“Our expertize lies in researching, developing and formulating marijuana products of the highest quality and the growth potential that vaping offers a company such as ours is enormous. Even outside of the marijuana sector’s current investment potential, there aren’t many products, in many sectors whose sales have tripled in the last few years, and there are even fewer products with the potential to triple again,” said Drew Lancaster, Ph.D., Head of Product Development at Genisis Biotech, Calgary.

“This is why we will be developing further our CBD oils specifically for vaping and specifically for medicinal use. Marijuana vaping is, and will be, the hot growth segment within the surging legal marijuana sector over the coming years and we intend to take full advantage from it,” added Drew Lancaster.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Recent MedScape Poll Shows Majority Of Doctors, Nurses And Pharmacists Now Fully Support Legalizing Marijuana

February 28th, 2019

A newly published survey by MedScape shows that the majority of U.S. doctors, nurses and pharmacists are now in favor of legalizing marijuana nationwide, and an even bigger super-majority are now in agreement with legalizing medicinal marijuana.

The results of the poll, which was conducted by Medscape Medical News, also show strong support for marijuana reforms from other medical professionals like psychologists, as well as those working in health business and administration.

Here’s how the healthcare professionals responded to the question; “Should Recreational Marijuana Be Legalized Nationally?”

  • Physicians: 53% support
  • Health Business/Administration: 72% support
  • Nurses: 57% support
  • Pharmacists: 54% support
  • Psychologists: 61% support

And when asked, “Should Medical Marijuana Be Legalized Nationally?” they replied as follows:

  • Physicians: 67% support
  • Health Business/Administration: 88% support
  • Nurses: 82% support
  • Pharmacists: 71% support
  • Psychologists: 82% support

In no category did less than a majority of medical professionals support legalizing recreational or medical marijuana.

Broader polling in recent years have also consistently shown that a growing majority of Americans support legalizing marijuana, and the new MedScape results indicate that medical professionals’ views on marijuana laws do not significantly differ from those of the general population.

“For many years we have assisted with research to many privately-owned U.S. companies and several U.S. state organizations to establish and determine marijuana’s effectiveness as a clinically proven medicine,” said Martin Milligan, PharmD, Director of Medical Services with Genisis Biotechnologies, Calgary, Canada.

“Although our research, and that of other companies too, will always be clinically proven before its use it is always its acceptance by the medical profession that justifies our research programs. The results of the last MedScape poll are a fantastic justification to the ever-increasing acceptance and use of medicinal marijuana by those whose reputations of their patient care are at stake. As a company we will always strive to provide an ever-growing number of clinically proven marijuana-based cures and treatments and the results of this MedScape poll justifies our efforts in providing them,” Milligan added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotech Set To Become A Major Positive Disruptor To The Canadian Healthcare Sector

February 22nd, 2019

Recently, Genisis Biotech have started to become noticed as a company to follow in the medicinal marijuana sector after recently reported news that they were in the process of a potential major acquisition which was only picked up on by a few sources.

In January, Genisis Biotech were reported to be in discussions, in conjunction with another company, to acquire a healthcare payment processing company who make payments to over 3,000 health providers. If true, this would represent a major acquisition that would immediately be accretive to Genisis Biotech.

This acquisition would make Genisis Biotech a considerably larger player in the medicinal marijuana sector and would be a major growth opportunity due the large amount of valuable resources that would become available with such an acquisition.

The acquisition would ensure immediate access to nearly 300 clinics, over 3,000 licensed practitioners and 2,870,000 registered patients. This would be significant and would be very favorable to the growth prospects of the company going forward.

Only last month, another Canadian marijuana company announced a partnership with a major online healthcare company in China, 360 Health. This partnership will further help facilitate the sector’s growth overseas and will form a major part of the medicinal marijuana’s international expansion process.

The parent company, 360 Security Technology, is a leading online service company in China with a market capitalization of over $20 billion USD as of February 14, 2019. The strength of the parent company is an important aspect of the story and this gives us more confidence when it comes to execution.

China represents the largest potential market share for medicinal marijuana and the country is slowly beginning to adopt a family primary care practice model in relation to it. This provides an opportunity for many companies to establish a presence in the country with a population of nearly 1.4 billion.

“Through organic and inorganic growth initiatives, we intend to significantly advance our fundamental business footprint and we are confident of a favorable outcome in relation to the recent developments involving a planned acquisition,” said Don Jennings, Director of Corporate Development at Genisis Biotech.

“This intended acquisition will immediately provide us with an asset that is already generating significant revenues. It would also make Genisis Biotech a major player in the medicinal marijuana sector and we are excited on the further growth prospects associated with this,” added Don Jennings.

Genisis Biotech already has in place several significant catalysts for growth and has the advantage of being led by a management team with a proven track record.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies Are Pleased To Announce The Appointment Of Mr. Terry Stanton As Chief Commercial Officer

February 16th, 2019

Genisis Biotechnologies, a leader in the research and commercial development of medicinal and pharmaceutical marijuana products and targeted therapies is pleased to announce the appointment of Terrence, (Terry), Stanton, BBA, as Chief Commercial Officer.

Mr. Stanton was most recently the Chief Operating Officer and Vice-President, Operations at a large U.S. based pharmaceuticals company., where he was responsible for the growth, marketing, and development of all operations for more than 45 of the company’s household named medicinal products, including marketing, personnel, and strategic activities.

Terry gained extensive experience during a tenure of more than 20 years with them, where he honed his analytical skills, specifically in the areas of finance, marketing, communications and development, P&L, merchandising, and corporate strategy.

He rose through the ranks from Director of Operations to National Vice-President Operations and Strategy and his responsibilities involved dealing with more than 1,300 pharmacist-owned locations across the U.S. and Canada.

From 2006 to 2011, Mr. Moffatt was Senior Director of Mergers and Acquisitions/Pharmacy Operations at Loblaw Companies Ltd. and participated in the successful acquisition of Shoppers Drug Mart. Terry also established the current set of operational standards for the 503-store pharmacy group.

Previous to this, Mr. Stanton was at World Vintners Inc. where he was Senior Vice-President Retail and Corporate Development, Corporate Secretary, and President Retail. Terry oversaw the company’s purchase and merger of two wine-producing and retail entities prior to their sale in 2008. He also developed and launched new wine brands specifically for big-box retailers and independent wine dealers.

“It is a pleasure to welcome Terry to our team. We are fortunate to have attracted a senior retail executive with extensive operational management skills in the pharmaceutical retail environment,” said Clive Mendelson, Chief Executive Officer at Genisis Biotechnologies.

“Terry’s experience in retail operations, merchandising, and corporate strategy will be invaluable as we prepare to launch many of our own developed products including our ultra-pure, THC-free, pharmaceutical CBD wellness products into the Canadian medicinal marijuana marketplace.”

Mr. Stanton graduated from the Humber Institute of Technology and Applied Learning with a Bachelor of Business Administration and has completed the Executive Development Program at York University’s Schulich School of Business.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotech To Create CBG And CBN Research And Development Program In Wake Of U.S. Farm Bill’s Legislation Of Hemp

February 8th, 2019

Genisis Biotech have announced that they will be creating a CBG and CBN research and development program in the wake of U.S. senate passing a Farm Bill late last year allowing legislation for the commercial cultivation of hemp in the U.S.

Hemp, as a plant, is no more than a cousin of marijuana and contains no THC, the psychoactive compound found in marijuana, but was outlawed alongside marijuana in the Marihuana Tax Act of 1937 due to its relationship with the marijuana plant.

The 2018 Farm Bill officially reclassifies hemp for commercial uses by removing hemp from the Controlled Substances Act and has moved regulation and enforcement of the crop from the Drug Enforcement Agency to the U.S. Department of Agriculture.

Hemp has hundreds of uses, from textiles and plastics to livestock feed and home cooking, but more importantly it has many medicinal applications which are yet to be discovered or fully realized due to the lack of available research.

It is well-known that hemp contains cannabinoids, used in the manufacture of CBD oil, which is now a clinically proven compound being used to treat epilepsy, anxiety, schizophrenia, heart disease, and cancer as well as a range of other illnesses.

Clinical research and development exploration will now be permitted at federal level in the U.S. into CBD‘s, CBGs, CBN’s and 113 other cannabinoids, as well as some 300 terpenes found in the industrial hemp plant, and with this the need for companies with proven clinical research facilities.

Genisis Biotech’s research in to CBD is well-proven although very little research has been conducted in to CBG and CBN.

Cannabigerol, (CBG), is a cannabinoid found in high concentrations in hemp, is non-psychoactive and is known to stimulate neurogenesis, (brain cell growth), and it is also antibacterial, anti-tumor, and helps with insomnia.

Cannabinol, (CBN), is also non-psychoactive and occurs naturally in hemp as the plant ages and limited research carried out to date shows it has many potential clinical uses ranging from being used as a sedative, a pain reliever, an antibiotic, an anti-inflammatory, an appetite stimulant, and as a glaucoma therapy.

Jonathon Rennie, PhD, Director of Cannabinoid Research with Genisis Biotech said, “Our ongoing clinical research programs in to CBD are already well-established. The creation of a new research program, which is to focus solely on CBG and CBN, will enable us to evaluate their true clinical and medicinal benefits independently from those of CBD.”

“We have already been approached by two large pharmaceutical companies in the U.S. who are wanting us to research a particular strain of CBN that could be potentially used to treat certain medical conditions. Furthermore, a large multi-national, agricultural bio-tech company have requested our services to help develop hemp cultivation to yield higher levels of CBG than that which naturally occurs. As a company we are very excited about the clinical potential that both CBN and CBG has to offer,” Rennie added.

Genisis Biotech will soon be announcing further details regarding this new research and development program and a possible location for the new research facility required to house it, although it has been confirmed that the facility will be Calgary which is where their current main facility is located.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies Announce 1st Phase Of 3 Phase Private Placement Program

January 25th, 2019

Genisis Biotechnologies, (the “Company”), wish to inform the investment public that they will be entering in to a series of 3 phases of brokered private placement with phase 1 starting on Monday February 4th, 2019.

The Private Placement is in respect to the issue and allotment of up to 2,650,000 units with phase 1 issue and allotment totaling 800,000 units at a price of U.S. $0.85 per unit.

Each unit, free of any commission to the Company, will be comprised of one common share of the Company, (a "Common Share") and one common share purchase warrant, (a "Warrant").

Each Warrant will be exercisable to acquire one common share, (a "Warrant Share"), for a period of 6 months following the closing date of the offering at an exercise price of $0.65 per Warrant Share.

The Common Shares and Warrants shall be subject to a 4 month hold period.

The private placement is being offered to allow the company to increase its medical marijuana bio-tech research and development in to treatment of clinical conditions and to increase its market share within the global medical marijuana industry sector.

Clive Mendelson, Chief Executive Officer of Genisis Biotech said, “We are pleased to announce that our first round of private placement funding will be starting early next year. This will allow us to further increase our research and development facilities, and with it our market share in both domestic and global markets. We welcome the opportunity of inviting new investment partners to our company and would like to confirm that our company’s ethos of ensuring we provide the most effective of patient care will remain the same as it always has.”

WFE Capital Limited have been appointed as the company’s preferred brokerage to oversee and assist with the 3 rounds of private placement funding. As such, WFE Capital will be entirely responsible for the placement and allocations of pre-IPO stock for both the Asia-Pacific region and Europe from their strategically placed offices in Hong Kong and London.

“We are privileged to have been appointed as Genisis Biotech’s preferred brokerage to facilitate their 3 rounds of private placement. Our previous involvements with Aurora and Cronos group, who are also both in the marijuana sector, and who have both become extremely successful since their flotations, are testament to the investment potential that this sector now has to offer investors,” said George Weinberg, Founder and Chairman with WFE Capital.

Completion of the Company’s private placement offering is expected to be completed within 6 months and subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and NYSE approvals the company will become listed soon after.

Anyone wishing to learn more about Genisis Biotech’s brokered private placement program may do so by contacting WFE Capital directly via info.hk@wfecapital.com or info.eu@wfecapital.com

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotech Confirm Trade Exhibition Stand At Toronto Marijuana Business Conference & Expo From September 4th to September 6th 2019

January 18th, 2019

Genisis Biotech are pleased to announce that they are to take a trade stand at this year’s Marijuana Business Conference & Expo, (MjBizConINT’L), which is being held at the Metro Toronto Convention Centre between September 4th and 6th.

The exhibition is one of many that MjBizCon are holding throughout the year with conferences at venues in New Orleans, Copenhagen and Las Vegas already confirmed.

MJBizConINT’L is a globally focused marijuana conference which convenes international leaders in marijuana investing, business and regulations and is considered to be the preeminent event related to the marijuana industry. It is expected to attract this year over 20,000 attendees and over 900 exhibitors to Toronto, and has now become the largest marijuana conference in the world.

The conference is primarily targeted towards decision makers who want to impact the global marijuana marketplace. As an industry, still very much in its infancy, marijuana now is poised to revolutionize the world economy. Attendees and exhibitors who want to learn and develop more of the international trade available from this sector, and what it has to offer them, will all be in attendance.

The conference is targeted towards virtually every aspect of the global marijuana industry, so whether you have a grow in Washington, a shop or two in Ontario or a packaging plant in Australia, it’s definitely worth visiting the exhibition.

“We consider that our company’s presence at such a prestigious exhibition is mandatory,” said Don Jennings, Director of Corporate Development at Genisis Biotech.

“The marijuana sector has very quickly become an industry in its own right. The advancements made, particularly in respect to its clinical and medicinal aspects, are already well-proven and these are now expected to continue as more research studies and development programs are established. As a company we believe that every aspect of the marijuana sector should be included within our company’s operational scope,” Jennings added.

“Our operational umbrella covers every aspect, from cultivation to research and product development and manufacture. We believe that this affords us unequivocal control over the end product and with it an assurance to our partners and customers that the products we have association with are clinically safe and proven for the purpose intended,” Jennings concluded.

Anyone interested to know more about Genisis Biotech’s trade stand at MJBizConINT’L should contact the company via info@genisisbiotech.com.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Mike Tyson Breaks Ground On 40-Acre Marijuana Resort Destination In California Following State’s Legalization Of Recreational Marijuana

January 15th, 2019

Former heavyweight champion Mike Tyson, with his company Tyson Ranch, is now one of California’s newest marijuana industry companies, breaking ground on a 40-acre ranch envisioned as a resort destination for growers and consumers of medicinal and recreational marijuana.

California legalized licensed medical marijuana use many years ago, but on January 1st the state also legalized recreational marijuana, and Tyson is looking to become a major player. Tyson, 51, broke ground last month on a “cannabis resort” to be located in California City, a town in the Mojave Desert located about a two-hour drive from Los Angeles.

Tyson Ranch is also a short drive from Edwards Air Force Base, and according to the report, “taking care of men and women who have served in the armed forces is a top priority” for Tyson Holistic, the company that will operate the Tyson Ranch resort.

Cannabidiol, (CBD), which is extracted from marijuana and does not bring the ‘high’ that is associated with tetrahydrocannabinol, (THC), is now being used by many veterans to treat cases of post-traumatic stress disorder or PTSD. It is also celebrated by advocates for its therapeutic properties, according to The Washington Post.

Tyson Holistic will produce high quality products including both CBD and THC as well as supporting research on the health benefits of marijuana. The ranch will reportedly be broken down as follows: 20 acres will be used for the cultivation of marijuana by ‘master growers,’ while the property will also feature facilities to train growers and those interested in the industry as well as an ‘edibles factory’.

Robert Hickman and Jay Strommen, two of Tyson’s business partners, and California City Mayor Jennifer Wood attended the groundbreaking ceremony. Wood, who excited by the opportunity and this use of her city’s land, said, “The ranch would help revitalize this town and boost the city’s economy by now being able to attract other marijuana-related companies.”

Tyson Holistic plans to partner with Flemington-based Almost Heaven Agriculture, a West Virginia greenhouse to grow and extract marijuana for use in its products.

Kevin Bell, a partner and chief operations officer for Tyson Holistic, said, “Officials with the company have been in West Virginia for about a week looking for opportunities to invest. We looked at lots of reclamation land and we have agreed to partner with an existing license holder, Almost Heaven Agriculture, to do a joint venture.”

Tyson Holistic, which is only in its fourth month of existence, already produces a hemp-infused water and a hemp infused pain-relief gel.

Martin Milligan, PharmD, Director of Medical Services with Genisis Biotech, the Calgary based company who were responsible for much or the research and development for Tyson Holistic’s hemp-infused product range said, “We wish the Tyson Ranch every success and we are privileged that our company were able to assist Tyson Holistic with their clinical tests. We look forward to continuing our partnership with them in the future.”

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies In Discussions With PepsiCo In Relation To CBD Infused ‘Functional Wellness Beverages’ Soft Drinks’

January 4th, 2019

Genisis Biotechnologies, are pleased to announce that they are in discussions to advise PepsiCo with their possible launch of CBD infused soft drinks which will they would market under the product brand as ‘functional wellness beverages’ and would cover global patents in 32 countries.

PepsiCo, one of the world’s largest beverage makers, recently confirmed that it is possibly looking at a line of CBD beverages in an attempt to take a market share of the medical marijuana sector in direct response to the ever-increasing legislation surrounding the use of both medicinal and recreational marijuana.

“Along with many others in the beverage industry, we are closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world,” PepsiCo CFO Hugh Johnston said in a statement.

“The space is evolving quickly and although no decisions have been made at this time we are currently in discussions with Genisis Biotechnologies on how best to safely formulate these soft drinks,” Johnston added.

CNBC reported that PepsiCo is also is in talks with another company to develop the distribution network of the product line, but neither PepsiCo nor the other company would confirm this.

Many large soda manufacturers have been looking for new opportunities in the marijuana sector in the wake of falling sales as consumers turn away from sugary soft drinks and expect the marijuana soft drink sector to be valued at potentially $50 billion a year globally.

Don Jennings, Director of Corporate Development at Genisis Biotechnologies wrote in a previous news release that, “Genisis Biotechnologies plans to enter the beverage space and is open to partnerships.”

And that the company, “Has expressed specific interest in the infused beverage space, and we intend to enter that market,” he wrote.

The CBD beverage boom comes as prices fall for water-soluble CBD isolate. The isolate can now be had for roughly $20 a gram, depending on quality and size of an order.

Other beverage companies have also been actively looking at marijuana partnerships in Canada, where recreational marijuana becomes legal next month.

In the past two months:

  • Canada’s Breakthru Beverage Group, a large distributor of beer, wine and liquor, inked a strategic partnership with a marijuana company for 10 million Canadian dollars (U.S. $7.5 million).
  • Molson-Coors Brewing Co. announced a joint venture with a Quebec-based company to develop nonalcoholic, cannabis-infused beverages.
  • “Our involvement with the soft drinks’ market will be of enormous significance to our company as it is a true reflection of our proven clinical research and development facilities that has allowed us this privileged opportunity,” Don Jennings added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotech Positioned For Significant Growth In 2019

December 21st, 2018

The marijuana industry is one of the most attractive growth markets for investors and such opportunities only appear once in a lifetime. During the last year, the marijuana industry recorded significant growth, and this is a trend that is expected to continue for years to come.

When it comes to investing in the marijuana sector, it is important to look for companies with leading management teams, attractive valuations, and significant growth prospects.

One company that meets this criterion is Genisis Biotech who have been in the middle of a major expansion and have been executing it flawlessly. During the last year, the company significantly advanced its fundamental story through organic and inorganic growth initiatives and they are now establishing themselves a strong position in the marijuana sector.

From acquisitions to strategic partnerships, the company has been laser focused on expanding its reach and increasing its overall market share. Due to this, the company is now being looked upon as having massive growth prospects and is establishing a keen interest from investors.

Part of Genisis Biotech’s expansion is to significantly increase its marijuana production capacity over the course of 2019. The company recently completed Phase I construction of its newest greenhouse facility, bringing it to a grow-ready state, pending final Health Canada approval.

In December, Genisis Biotech reported a major development and announced that it was planning to acquire a Canadian marijuana producer. Once the acquisition has been completed it will represent a multi-faceted growth opportunity for the company and this acquisition is expected to quickly prove to be accretive.

Through this acquisition, Genisis Biotech will be able to leverage extraction, and product innovation to sell high-margin medical marijuana directly to a patient base for the first time. This patient base will then also have access to Genisis Biotech’ differentiated, high margin derivative products including capsules, oils and oral sprays.

The proposed acquisition creates a new Canadian medical marijuana leader that will operate the country’s largest national clinic network and will have improved operational scale with planned annual capacity of approximately 138,000 kg (including committed supply agreements), Canadian and expanded global distribution, and a robust branding and product development platform.

The company also plans to gain national medical distribution through an agreement with Shoppers Drug Mart and gain national retail distribution through Fire & Flower, Starbuds and the emerging One Plant network. Through the acquisition, Genisis Biotech intends to capitalize on high growth opportunities and leverage international expansion across four verticals: Marijuana Production, Health and Wellness, Marijuana Education and the Consumer Experience.

This acquisition significantly improves Genisis Biotech’s position in the international marijuana market. The company will also benefit from a previously announced joint venture with a German pharmaceutical wholesaler. Genisis Biotech expects to use this relationship to access the world’s largest medical marijuana market serving more than 82 million people, with access to approximately 20,000 pharmacies.

About Genisis Biotech

At Genisis Biotechnologies our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Canadian Companies Now Becoming Established As World Leaders In The Global Legal Marijuana Industry

December 18th, 2018

Despite an ever-increasing number of countries and states worldwide now passing legislation allowing for the legal use of medical marijuana the recent legislation allowing for the recreational use of marijuana in Canada will now establish the country’s companies involved in this sector as world leaders.

The sector’s research and development focused companies are being forecast as those who are set to gain the most as for some time now Canada has been one of only 3 countries in the world who have a carefully-monitored and licensed national medical marijuana program. This has resulted in companies who operate outside of Canada, yet want research in to marijuana undertaken, needing to use their licensed research and development programs.

Unlike the United States, where marijuana is still a Schedule 1 drug, ("no accepted medical use"), and research permits are notoriously difficult to obtain, medical and recreational marijuana is already legal and regulated in Canada at the Federal level.

Bio tech companies, doctors, universities and newly-emerging licensed producers have a rather unique opportunity right now in Canada in that only a few other countries in the world have; direct, legal, regulated access to whole-plant marijuana for research purposes.

Canada is now unquestionably the world leader in terms of a regulated marijuana framework, and the research and development undertaken by Canadian companies will be, and is of, enormous benefit to states and countries who have yet to pass legislation.

Many doctors and physicians worldwide already know and understand the amazing possibilities the marijuana plant brings, and as the body of clinical research proving these possibilities grows, the more mainstream acceptance for, and understanding of, these possibilities will also grow.

“It's nice to know Canada is emerging on the forefront of global medical marijuana research. Research is very important in showing the various, viable clinical applications for marijuana. While many patients worldwide have positive anecdotal evidence to share, doctors want in-depth, peer-reviewed research, and that is what we are able to provide,” said Jonathon Rennie, PhD, Director of Cannabinoid Research at Genisis Biotechnologies, Calgary, Canada.

“Our clinical research partnership programs in to marijuana with some of the world’s largest pharma companies are literally expanding every week as we find more and more treatments and cures using CBD as the medicine’s base compound. This research has enormous possibility for marijuana-based products soon being used as the first course for certain treatments as acceptance of its clinical use grows,” Rennie added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Medical Marijuana Approval Now Sweeping Across Europe, Market Set To Grow To 60 Billion Euros In 4 Years

December 1st, 2018

In March 2017, the German parliament voted for the legalization of marijuana for medicinal purposes. A year on, much has changed in this respect as many other EU member states have been closely monitoring Germany’s progress in the legalization of medical cannabis and are now following suit.

In Portugal, parliament is currently considering the legalization of marijuana for medical use and they already have had legal marijuana plantations since 2017, which grow the plant for export.

Denmark, as of January 1st, 2018, has initiated a four-year medical marijuana pilot program which allows companies to apply for admission of marijuana products at the Danish Medicines Agency.

The Italian Ministry of Health has been coordinating and monitoring the legalization process for medical marijuana and since November 2015 it has had the power to distribute cultivation, production, possession and use permits.

In Ireland, a landmark decision made in November last year announced by their Department of Health said that it would issue its first license for the use of marijuana as a treatment for chronic pain.

The UK and a list of many other EU countries who are now embarking on medical marijuana legislation is growing exponentially and will eventually lead to all EU countries sharing a common legislation towards its clinical use.

Europe is being forecast to be the world’s largest legal marijuana market in just 4 years with a potential value of over 60 billion Euros, nearly $70 billion.

This represents a market value increases of nearly 1,000% from its current 500 million Euro value. Medicinal marijuana is already legal in 14 countries in Europe but legislation is expected to increase this number considerably as the entire EU region now begin to improve patient access to marijuana-based products. These numbers are for medicinal use only and are likely to increase as legislation allowing for the recreational use of marijuana is also expected to increase considerably too.

“The EU will very soon become the world’s largest user of medical marijuana as blanket reform and legislation will ultimately be agreed by all countries. Once this happens, we anticipate medical marijuana demand to increase by over $50 billion a year, and that’s conservative as a $70 billion increase is being mentioned by some market strategists should recreational legislation start to be passed,” said Sarah McMasters, Ph.D., Simon Hoffer, Commercial Director at Genisis Biotechnologies, Calgary, Canada.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genetically Modified Medical Cannabis Set To Revolutionize The Clinical Approval Of Marijuana Derived Medicines

November 22nd, 2018

Legal hurdles that previously restricted exploring the specific properties and benefits of marijuana’s medicinal properties will now soon soon fall in the wake of the US Food and Drug Administration’s, (FDA), first approval of a cannabis-derived drug, Epidiolex.

“Now that the FDA has approved Epidiolex we have a clear recognition that this plant has more potential than people credited it for, and that has reverberations that are scientific as well as legal”, says Daniele Piomelli, director at the University of California.

The expected increase in FDA approvals is fantastic news for biotech companies who are involved in the medical marijuana sector as it will increase the demand for cannabinoids that they are able to develop through genetic engineering. These products will ultimately be purer and more effective than those obtained through the current methods of extraction, and in turn will afford patients greater symptom relief.

“The medical marijuana sector is entering a biotech gold rush right now and following the FDA’s recent approval I fully expect to see many more approvals very soon, and not just from the U.S. either. If it passes FDA approval it will meet with every other county’s federal approval too,” says Oliver Kayser, a biotech engineer at the Technical University of Dortmund in Germany.

Most researchers and market analysts now foresee Canadian medical marijuana bio-research companies benefiting the most from the FDA approval of Epidiolex due to them already having far greater research facilities as a result of their longer established federal legislation of medical marijuana.

One such company who have been researching and developing genetically modified marijuana for the treatment of certain conditions is Genisis Biotechnologies in Calgary, Canada.

“Genetically modified medical marijuana is something we have been researching for several years now as it allows for specific strains of CBD, each with their own unique clinical benefits, to become prevalent during plant propagation,” said Jonathon Rennie, PhD, Director of Cannabinoid Research at Genisis Biotechnologies.

“The FDA approval to such a process will be of enormous clinical benefit to physicians, doctors and patients worldwide and our recent partnerships with several companies to develop a CBD specific for the treatment of Leukemia will soon be followed with further strains developed specifically to target the treatment of other unmet conditions,” Rennie added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies Announce Research Program Focused On Central Nervous System Disorders

November 2nd, 2018

Genisis Biotechnologies have recently announced their intention to set up a dedicated research program focused solely on curing conditions and disorders of the central nervous system using specific cannabinoids.

The company will run the research as part of their RDT program, (Research, Develop, Test), which has been in existence since 2014 and was set-up specifically for dedicated research purposes.

There are many different types of central nervous system disorders, some of which include epilepsy, migraine, Alzheimer’s disease, Parkinson’s disease, Tourette syndrome, multiple sclerosis, meningitis and bipolar disorder.

With the exception of epilepsy, central nervous system disorders are not yet listed as ‘approved’ for treatment by medical marijuana although there are some that allow for it which is the primary reason why Genisis Biotechnologies want to provide more detailed clinical research to the treatment of such disorders.

“We take our clinical research responsibilities very seriously and we do not accept defeat when a patients’ improved well-being and health is at stake.

Although the project ahead of us is extremely complex we are extremely optomisic with regard to the clinical outcome,” said Martin Milligan, PharmD, Director of Medical Services at Genisis Biotechnologies.

“Although there are many conditions related to the central nervous system, previous research has shown us that most are treatable with a very similar strain of CBD. The focused research that we are about to enter in to is already being forecast to be a success by the team carrying out the research.”

Genisis Biotechnologies expect the program to last at least 2 years and have advised that they will release updates at regular intervals during the program.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Genisis Biotechnologies Announce Agreement To Form An Exclusive, Worldwide Partnership For CBD-Infused Medicinal Strip Products

October 26th, 2018

Genisis Biotechnologies have announced the execution of a definitive license, development and supply agreement with a global leader in medical marijuana production and distribution.

Pursuant to the agreement, the two companies will co-develop and commercialize medicinal film products infused with CBD.

Under the Agreement, Genisis Biotechnologies will fund 80% of the costs associated with the development of the CBD-infused product range and will also receive a fixed single-digit royalty on net product sales. The other company, who cannot yet be named due to a non-disclosure agreement, will have the exclusive, worldwide marketing and distribution rights for the co-developed products.

In connection with the agreement, the parties have also executed a subscription agreement pursuant to which a strategic investment in Genisis Biotechnologies by way of a non-brokered private placement. Pursuant to the Private Placement, 1,428,571 common shares will be purchased at an undisclosed price which has been proposed in the non-binding letter of intent between the parties on October 9th, 2018.

“With us having a Health Canada compliant and licensed facility for pharmaceutical film manufacturing, we are excited to establish this important partnership with a global leader in the medicinal and adult-use marijuana industry, and a company that shares our enthusiasm about the prospects for thin film CBD delivery,” said Simon Hoffer, Commercial Director at Genisis Biotechnologies, Calgary.

“Both companies see a world where innovative, pharmaceutical-grade marijuana products are made available to adult consumers and patients, and we are looking forward to working to make that a reality,” Hoffer added.

“Over the long-term, we believe a significant portion of the global marijuana market will be focused on non-combustible products,” said Don Jennings, Director of Corporate Development at Genisis Biotechnologies.

“Through this partnership, we look forward to co-developing film products infused with marijuana that we intend to market and distribute in Canada and other markets around the world as regulations permit,” Jennings added.

The product availability is expected to take approximately 3 months before it becomes widely available and will initially only be available under prescription although both companies are looking to further develop the product for use with different treatment and also in different flavors.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Inaugural International MJBizCon Event Hosted By Marijuana Business Daily Cannabis Hailed A Resounding Success In Toronto

September 14th, 2018

Following the success of previous marijuana related conferences and exhibitions held in Canada over the past few years by such companies as Lift Expo, O’Cannabiz, and Grow Up Cannabis, last week the US-based trade journal, Marijuana Business Daily, brought its successful US-based MJBizCon event series to Toronto for its inaugural international foray.

The result was considered to be ‘one of the most professionally-run conferences’ as reported by those exhibiting and also by those who attended, and was deemed to have ‘a truly international approach to exploring the cannabis industry’, which included speeches and seminars from Israeli research labs, Genisis Biotechnologies and also detailed Latin American business opportunities.

David Meiri, an Israeli medical cannabis researcher, who has been credited in identifying the cannabis strains that are most effective in controlling symptoms of autism spectrum disorder in children, gave a speech which confirmed the ongoing developments in the clinical effects of CBD for autism.

His research has proven that the diminishment of autism symptoms, which was previously credited to the non-intoxicating cannabinoid CBD, can be improved significantly when using a strain that blends CBD with a small amount of the intoxicating cannabinoid THC. This brought improvements in 100% of test subjects.

Another speech which received great accolade was delivered by Don Jennings, Director of Corporate Development at Genisis Biotechnologies, Canada.

Jennings explained how their marijuana-based drug Geniflexin, used for the treatment of PTSD, is nearing the stage where it can be presented for FDA approval and that the company have in their pipeline several other marijuana-based drugs, for various conditions, that they will present to the FDA once Geniflexin has been granted final approval.

Alfredo Pascual, a Germany-based public policy consultant who specializes in international cannabis markets and regulations told a packed audience how some Latin American countries are embracing the opportunity that marijuana legislation is presenting them, particularly in regard to the plant’s cultivation.

Pascual explained how Colombia, Uruguay, Brazil, Paraguay and Peru are all now developing business and investment opportunities, which at present are not nearly as strong as they are in the United States and Canada, are nevertheless making progress that is paving the way for opportunities in the near future.

Colombia, Uruguay, Brazil, Paraguay and Peru were mentioned in particular as the countries that will be able to capitalize the most in relation to the export of cannabis and related products.

As a direct result of the event’s success plans are already in place to host the same event in Toronto again next year with Marijuana Business Daily making public the dates as soon as they are known.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Australian Study Shows That Even Low CBD Extracts Can Treat Most Epileptic Seizures With THC Now Also Benefiting Epilepsy Patients

August 26th, 2018

It’s been widely believed that CBD is the compound in cannabis with medicinal value, but a new study out of Australia shows that THC shouldn’t be discounted in medical use either.

A new clinical trial suggests that less appears to be more when it comes to treating epilepsy with the marijuana extract cannabidiol.

The study, out of the University of Sydney, looked at parents who turned to medicinal cannabis to treat epileptic seizures in their children, many of who were getting their drugs through the black market.

Researchers found that most of the strains that the parents were using actually contained quite a low percentage of CBD, but regardless of that, over 75 percent of parents found that the medication was effective at reducing seizures.

"Although the extracts we analyzed contained low doses of CBD, three in four were still reported as effective, indicating the importance of researching the cannabis plant in its entirety for the treatment of epilepsy," said Iain McGregor, one of the authors of the study.

The patients were getting extracts that also contained THC, the psychoactive component of the cannabis plant, but not enough to impair their performance, yet still resulted in a seizure reduction of 75 to 100 percent.

And that was not the only benefit. 35 percent also showed improved cognition and 24 percent showed improvement in language skills, both of which were previously unrecognized benefits.

"Our research indicates there is a definite role for cannabinoids for the treatment of epilepsy, both CBD and THC play a key role. The patients did not experience any side effects, such as tiredness, decreased appetite, diarrhea or signs of liver damage as they would with normal pharmacological treatment," Dr. McGregor said. "And this alone warrant further clinical research so we can develop even more effective medicines."

“These results confirm the findings of our own independent research and testing,” said Drew Lancaster, Ph.D., Head of Product Development with Genisis Biotechnologies, Calgary, Canada.

“Recently, epilepsy has been the key focus of some of our most exhaustive research programs, both in-house and in partnership with other companies, as it is a disease with unmet needs to which medical marijuana has a proven benefit to sufferers. Ironically enough, it was an epilepsy drug that recently became the first FDA approved cannabis derived medicine. This has firmly established medical marijuana’s future in medicine.”

“We now expect many more FDA approvals of cannabis derived medicines, particularly so with the proven advancements in genetically modified strains of cannabis that can be propagated to produce specific CBD, as well as THC, that are already proven to be of benefit to patients suffering from specific conditions,” Lancaster added.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

In Partnership With Another Canadian Company, Genisis File Applications With The FDA To Begin Clinical Trials Of Marijuana-Based Medication

August 4th, 2018

Genisis Biotechnologies, in partnership with another Canadian medical marijuana-based bio-tech company, have filed two applications with the U.S. Food and Drug Administration, (FDA), requesting permission to begin clinical studies to test their pharmaceutical grade marijuana-based therapies in easing symptoms associated with Huntington’s disease and multiple sclerosis.

The two companies have also requested a meeting with FDA officials to discuss the development process for an investigational new drug, (IND). A pre-IND meeting helps create a strategy for the drug development process by reviewing the clinical trial design, sharing ideas, and understanding the specific expectations and requirements for a future IND application. This step, in turn, may shorten the time necessary to bring the product to market.

“The filing of these applications with the FDA brings us one step closer to helping persons suffering from these debilitating diseases. As a company, we are committed to researching and developing marijuana-based medicines which will improve the lives of people around the world,” said Sarah Blackwall, Ph.D., Director of Formulation Sciences at Genisis Biotechnologies, Calgary.

“The Genisis team expects many advantages by requesting a pre-IND meeting,” Blackwall added.

If approved, the companies will conduct one of the first-ever clinical trials to assess the safety and effectiveness of using a natural botanical marijuana extract as a potential treatment for patients with Huntington’s disease and multiple sclerosis.

The clinical trials should generate new data regarding the benefits of using marijuana -based medicine on clinical outcomes, eventually leading to successful commercial drug development.

Preliminary studies have shown that cannabidiol, the non-psychoactive constituent of cannabis oil, displays neuro-protective qualities. As such, Genisis Biotechnologies’ expects the clinical study will produce positive results and show benefits to treat these patients.

“Our unique scientific approach sets us apart from others in the industry, and we are working hard to create new and innovative pathways geared towards helping doctors treat conditions and to alleviate the suffering of patients,” Blackwall said.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Results Of 3 Year Cancer Treatment Research Trials Deemed A Resounding Clinical Success

July 22nd, 2018

Results of a 3-year test in to the use of medical marijuana for treatment of cancer patients by Genisis Biotechnologies has just been released and deemed a ‘clinical success’.

The trials which involved over 300 patients, all with various stages and forms of cancer were conducted to determine if medical marijuana could assist with a cancer patient’s treatment and prognosis. The trials also included treatment for alleviating the symptoms patients suffer after receiving chemotherapy and radiotherapy.

The clinical results are soon to be published to Health Canada detailing the exact cannabinoid strains and doses used but the trials determined that in over 50% of patients their tumors did not increase in size with the majority reducing in size, some to the point that the tumor had reduced in size by 75%.

The results for alleviating the nausea, vomiting, diarrhea and loss of appetite experienced after chemotherapy and radiotherapy have impressed even the greatest of skeptics with over 85% of patients reporting that their medical marijuana medication alleviated the symptoms where they were no longer a concern.

“Let’s be clear, we are not saying we have a miracle cancer cure, but what these tests prove beyond doubt is that medical marijuana has a place in medicine as an effective treatment to cancer patients,” said Martin Milligan, PharmD, Director of Medical Services.

“We are now committed even more than before to pursue this research and eventually we believe that we will make a significant breakthrough in medical marijuana cancer treatment which will ultimately be of enormous benefit to the millions of people worldwide,” Milligan added.

Genisis Biotechnologies would like to thank all of the patients who were involved with their clinical trials and are still carrying out ongoing assessments with them.

Anyone interested in assisting Genisis Biotechnologies with future clinical trials are welcome to make contact via clinical@genisisbiotech.com.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Global Medical Marijuana Market Sector Now Projected To Reach More Than $55 Billion By 2022

June 15th, 2018

The global medical marijuana market sector is expected to grow significantly from the U.S. $8.28 billion that it was worth in 2017 to a conservative estimate of more than U.S. $55 billion in 2022, a staggering 500% plus increase from 2018 to 2022, according to a new report by Grand View Research, Inc.

Factors propelling the growth of medical marijuana market are growing awareness regarding the benefits of its various applications, increasing demand for marijuana in the treatment of various diseases, and growing number of research and development activities.

Key Findings of the Grand View Research Market Report:-

  • Based on the medical application, the chronic pain segment held the major share of the global market due to hundreds of chemical compounds found in marijuana which help in treat pain management.
  • Based on the chemical derivatives, the CBD holds the major share of the global medical marijuana market, owing to increasing research and development activities along with the growing demand in application such as capsules, tincture, gum, vape oil, and bath products.
  • Geographically, North America holds the largest share in the global medical marijuana market and is expected to register high growth rate over the forecast period due to the growing number of U.S. states legalizing the use of marijuana for medical applications.
  • The rest of the world, particularly Europe, is expected to add the greater percentage gains as legislation becomes more widespread in the entire region with Asia-Pacific also increasing considerably, led by Australia whose legislation program has already started.

“Our own independent findings earlier this year resulted in very similar growth to that detailed in this report. The investment potential of medical marijuana is unequivocal but despite this it is the benefits that patients worldwide now enjoy which is of primary importance to us. Our clinical research in to finding greater patient benefits and cures will continue until we believe there are no more to find and our determination will ensure this happens,” said Don Jennings, Director of Corporate Development with Genisis Biotechnologies, Calgary, Canada..

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Medical Marijuana Investment Demand Set To Explode As FDA Approve First Medical Marijuana Derived Drug

June 16th, 2018

Medical marijuana investment demand is now set to explode following the recent approval by the FDA of the first marijuana derived drug, Epidiolex, which successfully passed the FDA’s stringent clinical trials for the treatment of two rare forms of pediatric epilepsy.

“This recent approval has now opened up the entire medical marijuana market for approval by the FDA,” said Philip Harrison, senior strategist with Bank of America Merrill Lynch, New York.

“This will push investment demand to a level that we have not yet experienced for this market sector. The demand was already quite spectacular but this announcement will ensure that every market savvy investor who can interpret this news as we do will be loading their client funds and personal portfolios with both direct and indirectly related medical marijuana investments,” Harrison added.

The sector’s investment potential is already well publicized with expected demand for medical marijuana set to increase from its current figure of just under $10 billion a year to nearly $60 billion by 2022, a growth of nearly 500%.

However, the recent approval by the FDA has some analysts placing the potential growth to nearer the $100 billion mark, with some predicting it could possibly be greater as more and more approvals are now expected by the FDA over the coming months.

“Our research and development programs are now establishing many more ways for patients to ingest their marijuana-based drugs and medications,” said Sarah Blackwall, Ph.D., Director of Formulation Sciences with Genisis Biotechnologies, Calgary, Canada.

“Medical marijuana is now being added to edibles such as cookies, chocolates, muffins, brownies, teas, and chewing gums. The patients who are recommended specific dosages of marijuana by their physicians can easily consume these edibles. The trend of producing edible products with medical marijuana is expected to drive the growth of the market as the demand for modes other than smoking is increasing,” Blackwall added.

Peter Freemantle, senior analyst with HSBC, London said, “Medical marijuana is no longer being looked upon as the should I, shouldn’t I asset, it is being looked upon as a must have asset. Whether it’s short-term or long-term trading that you favor it has all the solutions for investors. Buy now, buy as much as you can because in 6 months you will be looking back and wishing you had bought more.”

“For some people, they need a proverbial safe to fall on their head to make them realize the potential an investment has,” said Peter Schiff, CEO of Euro Pacific Capital.

“But at some point, people are going to figure out what's going on. By the time the crowd has already figured it out it's going to be very expensive to buy in to the medical marijuana sector, so why wait, if ever there was an opportunity it’s now to ensure you benefit from all its further gains,” Schiff concluded.

About Genisis Biotech

At Genisis Biotech our in-house research and development programs are established, first and foremost, to revolutionize the clinical benefits of medicinal marijuana and to provide products which ensure the superior care for patients through every stage of their medical journey. Our goal is to ensure that they receive and benefit from the most effective clinically proven treatments for all chronic conditions and pain.

For more information, visit: www.genisisbiotech.com

Contact

At Genesis Biotechnologies we value your interaction with us, so please feel free to contact us regarding any general inquiries you may have using the contact form on this page.

For Investor Relations related inquiries please use the form on our Investor Relations page.

Genisis Biotechnologies,
Commercial Drive,
Calgary,
Alberta,
T3Z 2A7,
Canada.
+1 587 997 1524